Author: "Iacovacci S" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Iacovacci S"' showing total 80 results

Start Over Author "Iacovacci S"

Sorry, I don't understand your search. ×

80 results on '"Iacovacci S"'

1. Late Mortality, Subsequent Malignant Neoplasms and Hospitalisations in Long-Term Survivors of Adolescent and Young Adult Hematological Cancers

Author: Trama, A, Vener, C, Lasalvia, P, Bernasconi, A, Zorzi, M, Andreano, A, Contiero, P, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Amodio, R, Bisceglia, I, Iacovacci, S, Vitale, M, Stracci, F, Gentilini, M, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Gatti, L, Boschetti, L, Corti, M, Rognoni, M, Coviello, E, Pesce, M, D'Orsi, G, Fanetti, A, De Lorenzis, L, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Trama A., Vener C., Lasalvia P., Bernasconi A., Zorzi M., Andreano A., Contiero P., Manneschi G., Falcini F., Castaing M., Filiberti R. A., Gasparotti C., Cirilli C., Amodio R., Bisceglia I., Iacovacci S., Vitale M. F., Stracci F., Gentilini M. A., Tumino R., Carone S., Sampietro G., Melcarne A., Gatti L., Boschetti L., Corti M., Rognoni M., Coviello E., Pesce M. T., D'Orsi G., Fanetti A. C., De Lorenzis L., Candela G., Savoia F., Pascucci C., Castelli M., Storchi C., Trama, A, Vener, C, Lasalvia, P, Bernasconi, A, Zorzi, M, Andreano, A, Contiero, P, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Amodio, R, Bisceglia, I, Iacovacci, S, Vitale, M, Stracci, F, Gentilini, M, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Gatti, L, Boschetti, L, Corti, M, Rognoni, M, Coviello, E, Pesce, M, D'Orsi, G, Fanetti, A, De Lorenzis, L, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Trama A., Vener C., Lasalvia P., Bernasconi A., Zorzi M., Andreano A., Contiero P., Manneschi G., Falcini F., Castaing M., Filiberti R. A., Gasparotti C., Cirilli C., Amodio R., Bisceglia I., Iacovacci S., Vitale M. F., Stracci F., Gentilini M. A., Tumino R., Carone S., Sampietro G., Melcarne A., Gatti L., Boschetti L., Corti M., Rognoni M., Coviello E., Pesce M. T., D'Orsi G., Fanetti A. C., De Lorenzis L., Candela G., Savoia F., Pascucci C., Castelli M., and Storchi C.
Abstract: Background: Increased success in the treatment of hematological cancers contributed to the increase of 5-year survival for most adolescent and young adults (AYAs) with these tumours. However, as 5-year survival increased, it became clear that AYA long-term survivors were at increased risk for severe late effects. Moreover, limited information on long-term cancer impact is available for AYAs, since most studies focused on children and adolescents. We aimed to assess various long-term outcomes on AYA survivors of hematological cancers. Methods: We selected patients diagnosed with a first primary hematological cancer between 1997 and 2006, in the Italian nationwide population-based cohort of AYA cancer survivors (i.e. alive at least 5 years after cancer diagnosis). Long-term outcomes of interest were: second malignant neoplasms (SMNs), hospitalizations and overall mortality. We calculated standardized incidence ratios (SIRs), standardized hospitalization rate ratios (SHRs) and standardized mortality rate ratios (SMRs). To study morbidity patterns over time, we modeled observed incidence rates by fitting flexible parametric models for nonlinear patterns and we used linear regression for linear patterns. Results: The study cohort included 5,042 AYA hematological cancer survivors of which 1,237 and 3,805 had a leukaemia and lymphoma diagnosis, respectively. AYA survivors were at substantially increased risk for SMN (SIR=2.1; 95%CI=1.7; 2.6), hospitalisation (SHR=1.5; 95%CI=1.5; 1.6), and mortality (SMR=1.4; 95%CI=1.2; 1.6) with differences between leukaemia and lymphoma survivors. The highest excess risks of hospitalisations were for infectious diseases, respiratory diseases, and diseases of blood and blood-forming organs. The morbidity pattern differs over time by morbidity type. Conclusions: Our results support the need for strict follow-up plans for survivors, and call for further study to better personalised follow-up plans for AYA cancer survivors.
Published: 2022

2. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study

Author: Botta, L, Gatta, G, Capocaccia, R, Stiller, C, Canete, A, Dal Maso, L, Innos, K, Mihor, A, Erdmann, F, Spix, C, Lacour, B, Marcos-Gragera, R, Murray, D, Rossi, S, Hackl, M, Van Eycken, E, Van Damme, N, Valerianova, Z, Sekerija, M, Scoutellas, V, Demetriou, A, Dusek, L, Krejci, D, Storm, H, Magi, M, Paapsi, K, Malila, N, Pitkaniemi, J, Jooste, V, Clavel, J, Poulalhon, C, Desandes, E, Monnereau, A, Katalinic, A, Petridou, E, Markozannes, G, Garami, M, Birgisson, H, Walsh, P, Mazzoleni, G, Vittadello, F, Cuccaro, F, Galasso, R, Sampietro, G, Rosso, S, Gasparotto, C, Maifredi, G, Ferrante, M, Torrisi, A, Sutera Sardo, A, Gambino, M, Lanzoni, M, Ballotari, P, Giacomazzi, E, Ferretti, S, Caldarella, A, Manneschi, G, Sant, M, Baili, P, Berrino, F, Trama, A, Lillini, R, Bernasconi, A, Bonfarnuzzo, S, Vener, C, Didone, F, Lasalvia, P, Del Monego, G, Buratti, L, Serraino, D, Taborelli, M, De Angelis, R, Demuru, E, Di Benedetto, C, Santaquilani, M, Venanzi, S, Tallon, M, Boni, L, Iacovacci, S, Russo, A, Gervasi, F, Spagnoli, G, Cavalieri d'Oro, L, Fusco, M, Vitale, M, Usala, M, Vitale, F, Michiara, M, Chiranda, G, Sacerdote, C, Maule, M, Cascone, G, Spata, E, Mangone, L, Falcini, F, Cavallo, R, Piras, D, Dinaro, Y, Castaing, M, Fanetti, A, Minerba, S, Candela, G, Scuderi, T, Rizzello, R, Stracci, F, Tagliabue, G, Rugge, M, Brustolin, A, Pildava, S, Smailyte, G, Azzopardi, M, Johannesen, T, Didkowska, J, Wojciechowska, U, Bielska-Lasota, M, Pais, A, Ferreira, A, Bento, M, Miranda, A, Safaei Diba, C, Zadnik, V, Zagar, T, Sanchez-Contador Escudero, C, Franch Sureda, P, Lopez de Munain, A, De-La-Cruz, M, Rojas, M, Aleman, A, Vizcaino, A, Almela, F, Sanvisens, A, Sanchez, M, Chirlaque, M, Sanchez-Gil, A, Guevara, M, Ardanaz, E, Canete-Nieto, A, Peris-Bonet, R, Galceran, J, Carulla, M, Kuehni, C, Redmond, S, Visser, O, Karim-Kos, H, Stevens, S, Gavin, A, Morrison, D, Huws, D, Botta L., Gatta G., Capocaccia R., Stiller C., Canete A., Dal Maso L., Innos K., Mihor A., Erdmann F., Spix C., Lacour B., Marcos-Gragera R., Murray D., Rossi S., Hackl M., Van Eycken E., Van Damme N., Valerianova Z., Sekerija M., Scoutellas V., Demetriou A., Dusek L., Krejci D., Storm H., Magi M., Paapsi K., Malila N., Pitkaniemi J., Jooste V., Clavel J., Poulalhon C., Desandes E., Monnereau A., Katalinic A., Petridou E., Markozannes G., Garami M., Birgisson H., Walsh P. M., Mazzoleni G., Vittadello F., Cuccaro F., Galasso R., Sampietro G., Rosso S., Gasparotto C., Maifredi G., Ferrante M., Torrisi A., Sutera Sardo A., Gambino M. L., Lanzoni M., Ballotari P., Giacomazzi E., Ferretti S., Caldarella A., Manneschi G., Sant M., Baili P., Berrino F., Trama A., Lillini R., Bernasconi A., Bonfarnuzzo S., Vener C., Didone F., Lasalvia P., Del Monego G., Buratti L., Serraino D., Taborelli M., De Angelis R., Demuru E., Di Benedetto C., Santaquilani M., Venanzi S., Tallon M., Boni L., Iacovacci S., Russo A. G., Gervasi F., Spagnoli G., Cavalieri d'Oro L., Fusco M., Vitale M. F., Usala M., Vitale F., Michiara M., Chiranda G., Sacerdote C., Maule M., Cascone G., Spata E., Mangone L., Falcini F., Cavallo R., Piras D., Dinaro Y., Castaing M., Fanetti A. C., Minerba S., Candela G., Scuderi T., Rizzello R. V., Stracci F., Tagliabue G., Rugge M., Brustolin A., Pildava S., Smailyte G., Azzopardi M., Johannesen T. B., Didkowska J., Wojciechowska U., Bielska-Lasota M., Pais A., Ferreira A. M., Bento M. J., Miranda A., Safaei Diba C., Zadnik V., Zagar T., Sanchez-Contador Escudero C., Franch Sureda P., Lopez de Munain A., De-La-Cruz M., Rojas M. D., Aleman A., Vizcaino A., Almela F., Sanvisens A., Sanchez M. J., Chirlaque M. D., Sanchez-Gil A., Guevara M., Ardanaz E., Canete-Nieto A., Peris-Bonet R., Galceran J., Carulla M., Kuehni C., Redmond S., Visser O., Karim-Kos H., Stevens S., Gavin A., Morrison D., Huws D. W., Botta, L, Gatta, G, Capocaccia, R, Stiller, C, Canete, A, Dal Maso, L, Innos, K, Mihor, A, Erdmann, F, Spix, C, Lacour, B, Marcos-Gragera, R, Murray, D, Rossi, S, Hackl, M, Van Eycken, E, Van Damme, N, Valerianova, Z, Sekerija, M, Scoutellas, V, Demetriou, A, Dusek, L, Krejci, D, Storm, H, Magi, M, Paapsi, K, Malila, N, Pitkaniemi, J, Jooste, V, Clavel, J, Poulalhon, C, Desandes, E, Monnereau, A, Katalinic, A, Petridou, E, Markozannes, G, Garami, M, Birgisson, H, Walsh, P, Mazzoleni, G, Vittadello, F, Cuccaro, F, Galasso, R, Sampietro, G, Rosso, S, Gasparotto, C, Maifredi, G, Ferrante, M, Torrisi, A, Sutera Sardo, A, Gambino, M, Lanzoni, M, Ballotari, P, Giacomazzi, E, Ferretti, S, Caldarella, A, Manneschi, G, Sant, M, Baili, P, Berrino, F, Trama, A, Lillini, R, Bernasconi, A, Bonfarnuzzo, S, Vener, C, Didone, F, Lasalvia, P, Del Monego, G, Buratti, L, Serraino, D, Taborelli, M, De Angelis, R, Demuru, E, Di Benedetto, C, Santaquilani, M, Venanzi, S, Tallon, M, Boni, L, Iacovacci, S, Russo, A, Gervasi, F, Spagnoli, G, Cavalieri d'Oro, L, Fusco, M, Vitale, M, Usala, M, Vitale, F, Michiara, M, Chiranda, G, Sacerdote, C, Maule, M, Cascone, G, Spata, E, Mangone, L, Falcini, F, Cavallo, R, Piras, D, Dinaro, Y, Castaing, M, Fanetti, A, Minerba, S, Candela, G, Scuderi, T, Rizzello, R, Stracci, F, Tagliabue, G, Rugge, M, Brustolin, A, Pildava, S, Smailyte, G, Azzopardi, M, Johannesen, T, Didkowska, J, Wojciechowska, U, Bielska-Lasota, M, Pais, A, Ferreira, A, Bento, M, Miranda, A, Safaei Diba, C, Zadnik, V, Zagar, T, Sanchez-Contador Escudero, C, Franch Sureda, P, Lopez de Munain, A, De-La-Cruz, M, Rojas, M, Aleman, A, Vizcaino, A, Almela, F, Sanvisens, A, Sanchez, M, Chirlaque, M, Sanchez-Gil, A, Guevara, M, Ardanaz, E, Canete-Nieto, A, Peris-Bonet, R, Galceran, J, Carulla, M, Kuehni, C, Redmond, S, Visser, O, Karim-Kos, H, Stevens, S, Gavin, A, Morrison, D, Huws, D, Botta L., Gatta G., Capocaccia R., Stiller C., Canete A., Dal Maso L., Innos K., Mihor A., Erdmann F., Spix C., Lacour B., Marcos-Gragera R., Murray D., Rossi S., Hackl M., Van Eycken E., Van Damme N., Valerianova Z., Sekerija M., Scoutellas V., Demetriou A., Dusek L., Krejci D., Storm H., Magi M., Paapsi K., Malila N., Pitkaniemi J., Jooste V., Clavel J., Poulalhon C., Desandes E., Monnereau A., Katalinic A., Petridou E., Markozannes G., Garami M., Birgisson H., Walsh P. M., Mazzoleni G., Vittadello F., Cuccaro F., Galasso R., Sampietro G., Rosso S., Gasparotto C., Maifredi G., Ferrante M., Torrisi A., Sutera Sardo A., Gambino M. L., Lanzoni M., Ballotari P., Giacomazzi E., Ferretti S., Caldarella A., Manneschi G., Sant M., Baili P., Berrino F., Trama A., Lillini R., Bernasconi A., Bonfarnuzzo S., Vener C., Didone F., Lasalvia P., Del Monego G., Buratti L., Serraino D., Taborelli M., De Angelis R., Demuru E., Di Benedetto C., Santaquilani M., Venanzi S., Tallon M., Boni L., Iacovacci S., Russo A. G., Gervasi F., Spagnoli G., Cavalieri d'Oro L., Fusco M., Vitale M. F., Usala M., Vitale F., Michiara M., Chiranda G., Sacerdote C., Maule M., Cascone G., Spata E., Mangone L., Falcini F., Cavallo R., Piras D., Dinaro Y., Castaing M., Fanetti A. C., Minerba S., Candela G., Scuderi T., Rizzello R. V., Stracci F., Tagliabue G., Rugge M., Brustolin A., Pildava S., Smailyte G., Azzopardi M., Johannesen T. B., Didkowska J., Wojciechowska U., Bielska-Lasota M., Pais A., Ferreira A. M., Bento M. J., Miranda A., Safaei Diba C., Zadnik V., Zagar T., Sanchez-Contador Escudero C., Franch Sureda P., Lopez de Munain A., De-La-Cruz M., Rojas M. D., Aleman A., Vizcaino A., Almela F., Sanvisens A., Sanchez M. J., Chirlaque M. D., Sanchez-Gil A., Guevara M., Ardanaz E., Canete-Nieto A., Peris-Bonet R., Galceran J., Carulla M., Kuehni C., Redmond S., Visser O., Karim-Kos H., Stevens S., Gavin A., Morrison D., and Huws D. W.
Abstract: Background: The EUROCARE-5 study revealed disparities in childhood cancer survival among European countries, giving rise to important initiatives across Europe to reduce the gap. Extending its representativeness through increased coverage of eastern European countries, the EUROCARE-6 study aimed to update survival progress across countries and years of diagnosis and provide new analytical perspectives on estimates of long-term survival and the cured fraction of patients with childhood cancer. Methods: In this population-based study, we analysed 135 847 children (aged 0–14 years) diagnosed during 2000–13 and followed up to the end of 2014, recruited from 80 population-based cancer registries in 31 European countries. We calculated age-adjusted 5-year survival differences by country and over time using period analysis, for all cancers combined and for major cancer types. We applied a variant of standard mixture cure models for survival data to estimate the cure fraction of patients by childhood cancer and to estimate projected 15-year survival. Findings: 5-year survival for all childhood cancer combined in Europe in 2010–14 was 81% (95% CI 81–82), showing an increase of three percentage points compared with 2004–06. Significant progress over time was observed for almost all cancers. Survival remained stable for osteosarcomas, Ewing sarcoma, Burkitt lymphoma, non-Hodgkin lymphomas, and rhabdomyoscarcomas. For all cancers combined, inequalities still persisted among European countries (with age-adjusted 5-year survival ranging from 71% [95% CI 60–79] to 87% [77–93]). The 15-year survival projection for all patients with childhood cancer diagnosed in 2010–13 was 78%. We estimated the yearly long-term mortality rate due to causes other than the diagnosed cancer to be around 2 per 1000 patients for all childhood cancer combined, but to approach zero for retinoblastoma. The cure fraction for patients with childhood cancer increased over time from 74% (95% CI 73–75) in 1998–
Published: 2022

3. Late Mortality, Subsequent Malignant Neoplasms and Hospitalisations in Long-Term Survivors of Adolescent and Young Adult Hematological Cancers

Author: Trama, A., Vener, C., Lasalvia, P., Bernasconi, A., Zorzi, M., Andreano, A., Contiero, P., Manneschi, G., Falcini, F., Castaing, M., Filiberti, R. A., Gasparotti, C., Cirilli, C., Amodio, R., Bisceglia, I., Iacovacci, S., Vitale, M. F., Stracci, F., Gentilini, M. A., Tumino, R., Carone, S., Sampietro, G., Melcarne, A., Gatti, L., Boschetti, L., Corti, M., Rognoni, M., Coviello, E., Pesce, M. T., D'Orsi, G., Fanetti, A. C., De Lorenzis, L., Candela, G., Savoia, F., Pascucci, C., Castelli, M., Storchi, C., Trama, A, Vener, C, Lasalvia, P, Bernasconi, A, Zorzi, M, Andreano, A, Contiero, P, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Amodio, R, Bisceglia, I, Iacovacci, S, Vitale, M, Stracci, F, Gentilini, M, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Gatti, L, Boschetti, L, Corti, M, Rognoni, M, Coviello, E, Pesce, M, D'Orsi, G, Fanetti, A, De Lorenzis, L, Candela, G, Savoia, F, Pascucci, C, Castelli, M, and Storchi, C
Subjects: adolescents and young adults (AYAs), long-term outcome, Cancer Research, Oncology, cancer survivor, hematological cancers, cancer survivors, hematological cancer, population-based cohort, long-term outcomes
Abstract: BackgroundIncreased success in the treatment of hematological cancers contributed to the increase of 5-year survival for most adolescent and young adults (AYAs) with these tumours. However, as 5-year survival increased, it became clear that AYA long-term survivors were at increased risk for severe late effects. Moreover, limited information on long-term cancer impact is available for AYAs, since most studies focused on children and adolescents. We aimed to assess various long-term outcomes on AYA survivors of hematological cancers.MethodsWe selected patients diagnosed with a first primary hematological cancer between 1997 and 2006, in the Italian nationwide population-based cohort of AYA cancer survivors (i.e. alive at least 5 years after cancer diagnosis). Long-term outcomes of interest were: second malignant neoplasms (SMNs), hospitalizations and overall mortality. We calculated standardized incidence ratios (SIRs), standardized hospitalization rate ratios (SHRs) and standardized mortality rate ratios (SMRs). To study morbidity patterns over time, we modeled observed incidence rates by fitting flexible parametric models for nonlinear patterns and we used linear regression for linear patterns.ResultsThe study cohort included 5,042 AYA hematological cancer survivors of which 1,237 and 3,805 had a leukaemia and lymphoma diagnosis, respectively. AYA survivors were at substantially increased risk for SMN (SIR=2.1; 95%CI=1.7; 2.6), hospitalisation (SHR=1.5; 95%CI=1.5; 1.6), and mortality (SMR=1.4; 95%CI=1.2; 1.6) with differences between leukaemia and lymphoma survivors. The highest excess risks of hospitalisations were for infectious diseases, respiratory diseases, and diseases of blood and blood-forming organs. The morbidity pattern differs over time by morbidity type.ConclusionsOur results support the need for strict follow-up plans for survivors, and call for further study to better personalised follow-up plans for AYA cancer survivors.
Published: 2022

4. Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials

Author: Vener, C., Rossi, S., Minicozzi, P., Marcos-Gragera, R., Poirel, H. A., Maynadie, M., Troussard, X., Pravettoni, G., De Angelis, R., Sant, M., Hackl, M., Van Eycken, E., Valerianova, Z., Sekerija, M., Pavlou, P., Dusek, L., Storm, H., Magi, M., Innos, K., Malila, N., Pitkaniemi, J., Velten, M., Bouvier, A. M., Jooste, V., Guizard, A. V., Launoy, G., Yonli, S. D., Woronoff, A. S., Nousbaum, J. B., Coureau, G., Monnereau, A., Baldi, I., Hammas, K., Tretarre, B., Colonna, M., Plouvier, S., D'Almeida, T., Molinie, F., Cowppli-Bony, A., Bara, S., Schvartz, C., Defossez, G., Lapotre-Ledoux, B., Grosclaude, P., Luttmann, S., Stabenow, R., Nennecke, A., Kieschke, J., Zeissig, S., Holleczek, B., Katalinic, A., Birgisson, H., Murray, D., Walsh, P. M., Mazzoleni, G., Vittadello, F., Cuccaro, F., Galasso, R., Sampietro, G., Rosso, S., Magoni, M., Ferrante, M., Sardo, A. S., Gambino, M. L., Ballotari, P., Giacomazzi, E., Ferretti, S., Caldarella, A., Manneschi, G., Gatta, G., Baili, P., Berrino, F., Botta, L., Trama, A., Lillini, R., Bernasconi, A., Bonfarnuzzo, S., Didone, F., Lasalvia, P., Del Monego, G., Magri, M. C., Buratti, L., Serraino, D., Dal Maso, L., Capocaccia, R., Demuru, E., Di Benedetto, C., Santaquilani, M., Venanzi, S., Filiberti, R. A., Iacovacci, S., Gennaro, V., Russo, A. G., Spagnoli, G., D'Oro, L. C., Fusco, M., Vitale, M. F., Usala, M., Vitale, F., Michiara, M., Chiranda, G., Cascone, G., Spata, E., Mangone, L., Falcini, F., Cavallo, R., Piras, D., Madeddu, A., Bella, F., Fanetti, A. C., Minerba, S., Candela, G., Scuderi, T., Rizzello, R. V., Stracci, F., Tagliabue, G., Rugge, M., Brustolin, A., Pildava, S., Smailyte, G., Azzopardi, M., Johannesen, T. B., Didkowska, J., Wojciechowska, U., Bielska-Lasota, M., Pais, A., Pontes, J. L., Miranda, A., Diba, C. S., Zadnik, V., Zagar, T., Escudero, C. S. -C., Sureda, P. F., de Munain, A. L., De-La-cruz, M., Rojas, M. D., Aleman, A., Vizcaino, A., Sanchez, M. J., Chirlaque, M. D., Eslava, M. G., Ardanaz, E., Galceran, J., Carulla, M., Bergeron, Y., Bouchardy, C., Mousavi, S. M., Bordoni, A., Visser, O., Rashbass, J., Gavin, A., Morrison, D., and Huws, D. W.
Subjects: Cancer Research, Survival, real-world data, randomized controlled trials (RCTs), tyrosine kinase inhibitor (TKI), population-based studies, Tyrosine kinase inhibitor (TKI), Randomized controlled trials (RCTs), survival, Real-world data, Europe, Oncology, cancer registries, chronic myeloid leukemia (CML), Chronic myeloid leukemia (CML), Cancer registries, Population-based studies
Abstract: This study was funded by the Compagnia di San Paolo, the Cariplo Foundation and the European Commission (grant number 801520 HP-JA-2017, Innovative Partnership for Action Against Cancer, iPAAC Joint Action). The sources of the funding played no role in designing the study, collecting, analyzing, or interpreting the data, writing the report, or deciding whether or not to submit the article for publication. This research was (partially) funded by Italian Ministry of Health "Ricerca Corrente" funds. Tyrosine kinase inhibitors (TKIs) have been improving the prognosis of patients with chronic myeloid leukemia (CML), but there are still large differences in survival among European countries. This raises questions on the added value of results from population-based studies, which use real-world data, compared to results of randomized controlled trials (RCTs) involving patients with CML. There are also questions about the extent of the findings on RCTs effectiveness for patients in the general population. We compare survival data extracted from our previous systematic review and meta-analysis of CML RCTs with the latest updated population-based survival data of EUROCARE-6, the widest collaborative study on cancer survival in Europe. The EUROCARE-6 CML survival estimated in patients (15-64 years) diagnosed in 2000-2006 vs. 2007-2013 revealed that the prognostic improvement highlighted by RCTs was confirmed in real-world settings, too. The study shows, evaluating for the first time all European regions, that the optimal outcome figures obtained in controlled settings for CML are also achievable (and indeed achieved) in real-world settings with prompt introduction of TKIs in daily clinical practice. However, some differences still persist, particularly in Eastern European countries, where overall survival values are lower than elsewhere, probably due to a delayed introduction of TKIs. Our results suggest an insufficient adoption of adequate protocols in daily clinical practice in those countries where CML survival values remain lower in real life than the values obtained in RCTs. New high-resolution population-based studies may help to identify failures in the clinical pathways followed there.
Published: 2022
Full Text: View/download PDF

5. Synthetic indicator of the impact of colorectal cancer screening programmes on incidence rates

Author: Zorzi M., Zappa M., Mazzoleni G., Morrone G., Caputo E., Galasso R., Citarella A., Sampietro G., Magoni M., Cavalieri D'Oro L., Ardizzone A., D'Argenzio A., Sciacca S., Pisani S., Ricci P., Giorno A., Ferretti S., Palma F., Serraino D., Iacovacci S., Quarta F., Filiberti R. A., Vitarelli S., Russo A. G., Carrozzi G., D'Orsi G., Fusco M., Sini G. M., Vitale F., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A. L., Cesaraccio R., Madeddu A., Fanetti A. C., Minerba S., Caldarella A., Candela G., Piffer S., Stracci F., Tagliabue G., Rugge M., Brustolin A., Castelli M., Zorzi M., Zappa M., Mazzoleni G., Morrone G., Caputo E., Galasso R., Citarella A., Sampietro G., Magoni M., Cavalieri D'Oro L., Ardizzone A., D'Argenzio A., Sciacca S., Pisani S., Ricci P., Giorno A., Ferretti S., Palma F., Serraino D., Iacovacci S., Quarta F., Filiberti R.A., Vitarelli S., Russo A.G., Carrozzi G., D'Orsi G., Fusco M., Sini G.M., Vitale F., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A.L., Cesaraccio R., Madeddu A., Fanetti A.C., Minerba S., Caldarella A., Candela G., Piffer S., Stracci F., Tagliabue G., Rugge M., Brustolin A., and Castelli M.
Subjects: Adenoma, Male, Colorectal cancer, colorectal cancer, Target population, colorectal cancer screening, NO, Screening programme, Single indicator, medicine, Humans, Mass Screening, National level, Early Detection of Cancer, Aged, Potential impact, business.industry, Incidence, Incidence (epidemiology), Gastroenterology, Colonoscopy, Colorectal Neoplasms, Female, Italy, Middle Aged, Occult Blood, Patient Compliance, Program Evaluation, medicine.disease, Colorectal cancer screening, business, Demography
Abstract: ObjectiveThe impact of a screening programme on colorectal cancer (CRC) incidence in its target population depends on several variables, including coverage with invitations, participation rate, positivity rate of the screening test, compliance with an invitation to second-level assessment and endoscopists’ sensitivity. We propose a synthetic indicator that may account for all the variables influencing the potential impact of a screening programme on CRC incidence.DesignWe defined the ‘rate of advanced adenoma on the target population’ (AA-TAP) as the rate of patients who received a diagnosis of advanced adenoma within a screening programme, divided by the programme target population. We computed the AA-TAP for the CRC Italian screening programmes (biennial faecal immunochemical test, target population 50–69 year olds) using the data of the Italian National Survey from 2003 to 2016, overall and by region, and assessed the association between AA-TAP and CRC incidence fitting a linear regression between the trend of regional CRC incidence rates in 50–74 year old subjects and the cumulative AA-TAP.ResultsIn 2016, the AA-TAP at a national level was 105×100 000, whereas significant differences were observed between the northern and central regions (respectively 126 and 149×100 000) and the South and Islands (36×100 000). The cumulative AA-TAP from 2004 to 2012 was significantly correlated with the difference between CRC incidence rates in 2013–2014 and those in 2003–2004 (p=0.009).ConclusionThe AA-TAP summarises into a single indicator the potential impact of a screening programme in reducing CRC incidence rates.
Published: 2019
Full Text: View/download PDF

6. Patient presentation, skin biopsy utilization and cutaneous malignant melanoma incidence and mortality in northern Italy: Trends and correlations

Author: Bucchi, L., Mancini, S., Zamagni, F., Crocetti, E., Dal Maso, L., Ferretti, S., Baldacchini, F., Giuliani, O., Ravaioli, A., Vattiato, R., Brustolin, A., Candela, G., Carone, S., Carrozzi, G., Cavallo, R., Dinaro, Y. M., Ferrante, M., Iacovacci, S., Mazzoleni, G., Musolino, A., Rizzello, R. V., Serraino, D., Biggeri, A., Stanganelli, I., Falcini, F., Bella, F., Cirilli, C., Curatella, S., Tumino, R., Galluzzo, C., Stracci, F., Gili, A., Ippolito, A., Michiara, M., Oriente, C., Piffer, S., Scuderi, T., Toffolutti, F., and Vittadello, F.
Subjects: Infectious Diseases, Dermatology
Abstract: The global increase in incidence of cutaneous malignant melanoma (CMM) occurring in the past decades has been partly attributed to increased diagnostic scrutiny of early lesions, with a potential phenomenon of overdiagnosis. The reported positive linear relation between skin biopsy rate and incidence of early CMM is compatible with this hypothesis.We explored the ecological association between the trends in annual dermatologic office visit rates, skin biopsy rates, incidence rates of in situ and invasive CMM by tumour thickness category, and CMM mortality rates in the Emilia-Romagna Region (northern Italy).Four cancer registries covering a population of 2,696,000 provided CMM incidence data for the years 2003-2017. Dermatologic office visit rates and skin biopsy rates were calculated using the Regional outpatient care database. All rates were age-standardized. Trends were described with the estimated average annual per cent change (EAAPC). Correlations were tested with the Spearman correlation coefficient.Incidence increased significantly. The increase was steeper for in situ CMM (EAAPC: men, 10.2; women, 6.9) followed by CMM0.8 mm thick (9.1; 5.2), but the rates grew significantly for most subgroups of CMMs ≥0.8 mm thick. Mortality decreased significantly among women (-2.3) and non-significantly among men. For dermatologic office visit rate and skin biopsy rate the EAAPC were, respectively, 1.7 and 1.8 for men and 1.2 and 0.9 for women. Annual dermatologic office visit rate correlated with skin biopsy rate in both sexes. However, the proportion of skin biopsies out of dermatologic office visits was constant across the years (range: men, 0.182-0.216; women, 0.157-0.191).In Italy, the increasing CMM incidence trend is, at least in part, genuine. Overdiagnosis-if any-is due to an increased patient presentation at dermatologic offices and not to a lower dermatologic threshold to perform biopsy.
Published: 2022

7. Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort

Author: Trama, A, Tittarelli, A, Barigelletti, G, Botta, L, Gatta, G, Tagliabue, G, Contiero, P, Guzzinati, S, Andreano, A, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Mazzucco, W, Mangone, L, Iacovacci, S, Vitale, M, Stracci, F, Piffer, S, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Ballotari, P, Boschetti, L, Pisani, S, Cavalieri D'Oro, L, Cuccaro, F, D'Argenzio, A, D'Orsi, G, Fanetti, A, Ardizzone, A, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Bernasconi, A, Trama, Annalisa, Tittarelli, Andrea, Barigelletti, Giulio, Botta, Laura, Gatta, Gemma, Tagliabue, Giovanna, Contiero, Paolo, Guzzinati, Stefano, Andreano, Anita, Manneschi, Gianfranco, Falcini, Fabio, Castaing, Marine, Filiberti, Rosa A, Gasparotti, Cinzia, Cirilli, Claudia, Mazzucco, Walter, Mangone, Lucia, Iacovacci, Silvia, Vitale, Maria F, Stracci, Fabrizio, Piffer, Silvano, Tumino, Rosario, Carone, Simona, Sampietro, Giuseppe, Melcarne, Anna, Ballotari, Paola, Boschetti, Lorenza, Pisani, Salvatore, Cavalieri D'Oro, Luca, Cuccaro, Francesco, D'Argenzio, Angelo, D'Orsi, Giancarlo, Fanetti, Anna C, Ardizzone, Antonino, Candela, Giuseppa, Savoia, Fabio, Pascucci, Cristiana, Castelli, Maurizio, Storchi, Cinzia, Bernasconi, Alice, Trama, A, Tittarelli, A, Barigelletti, G, Botta, L, Gatta, G, Tagliabue, G, Contiero, P, Guzzinati, S, Andreano, A, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Mazzucco, W, Mangone, L, Iacovacci, S, Vitale, M, Stracci, F, Piffer, S, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Ballotari, P, Boschetti, L, Pisani, S, Cavalieri D'Oro, L, Cuccaro, F, D'Argenzio, A, D'Orsi, G, Fanetti, A, Ardizzone, A, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Bernasconi, A, Trama, Annalisa, Tittarelli, Andrea, Barigelletti, Giulio, Botta, Laura, Gatta, Gemma, Tagliabue, Giovanna, Contiero, Paolo, Guzzinati, Stefano, Andreano, Anita, Manneschi, Gianfranco, Falcini, Fabio, Castaing, Marine, Filiberti, Rosa A, Gasparotti, Cinzia, Cirilli, Claudia, Mazzucco, Walter, Mangone, Lucia, Iacovacci, Silvia, Vitale, Maria F, Stracci, Fabrizio, Piffer, Silvano, Tumino, Rosario, Carone, Simona, Sampietro, Giuseppe, Melcarne, Anna, Ballotari, Paola, Boschetti, Lorenza, Pisani, Salvatore, Cavalieri D'Oro, Luca, Cuccaro, Francesco, D'Argenzio, Angelo, D'Orsi, Giancarlo, Fanetti, Anna C, Ardizzone, Antonino, Candela, Giuseppa, Savoia, Fabio, Pascucci, Cristiana, Castelli, Maurizio, Storchi, Cinzia, and Bernasconi, Alice
Abstract: Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scarce. This study assessed the risk of subsequent malignant neoplasms (SMNs) to identify the most common SMNs to be considered in follow-up care. Methods: Population-based cancer registries retrospectively identified first primary tumors (between 1976 and 2013) and SMNs in AYAs (15-39 years old at their cancer diagnosis). AYA cancer survivors were those alive at least 5 years after their first cancer diagnosis. The excess risk of SMNs was measured as standardized incidence ratios (SIRs) and absolute excess risk together with the cumulative incidence of SMNs. Results: The cohort included 67,692 AYA cancer survivors. The excess risk of developing any SMN (SIR, 1.6; 95% confidence interval, 1.5-1.7) was 60%. The excess risk of SMNs was significantly high for survivors of lymphomas; cancers of the breast, thyroid, female genital tract, digestive organs, gonads, and urinary tract; and melanomas. The cumulative incidence of all SMNs in AYA cancer survivors within 25 years of their first cancer diagnosis was approximately 10%. Subsequent tumors contributing to approximately 60% of all SMNs were breast cancer, colorectal cancer, corpus uteri cancer, and ovarian cancer in females and colorectal cancer, bladder cancer, prostate cancer, lung cancer, and lymphomas in males. Conclusions: These results highlight the need to personalize follow-up strategies for AYA cancer survivors.
Published: 2022

8. Susceptibility of human liver cell cultures to hepatitis C virus infection

Author: Carloni, G., Iacovacci, S., Sargiacomo, M., Ravagnan, G., Ponzetto, A., Peschle, C., Battaglia, M., and Gerlich, W. H., editor
Published: 1993
Full Text: View/download PDF

9. The economic impact of rectal cancer: A population-based study in Italy list of authors

Author: Gigli A., Francisci S., Capodaglio G., Pierannunzio D., Mallone S., Tavilla A., Lopez T., Zorzi M., Stracci F., Busco S., Mazzucco W., Lonardi S., Bianconi F., Russo A. G., Iacovacci S., Serraino D., Manneschi G., Fusco M., Cusimano R., Rugge M., Guzzinati S., Gigli A., Francisci S., Capodaglio G., Pierannunzio D., Mallone S., Tavilla A., Lopez T., Zorzi M., Stracci F., Busco S., Mazzucco W., Lonardi S., Bianconi F., Russo A.G., Iacovacci S., Serraino D., Manneschi G., Fusco M., Cusimano R., Rugge M., and Guzzinati S.
Subjects: Administrative databases, Administrative databases, Cancer registry, Cost analysis, Patterns of care, Prevalence, Real-world data, Cross-Sectional Studies, Delivery of Health Care, Health Care Costs, Humans, Italy, Health Expenditures, Rectal Neoplasms, lcsh:R, Patterns of care, Cost analysis, Prevalence, lcsh:Medicine, Cancer registry, Settore MED/42 - Igiene Generale E Applicata, Real-world data
Abstract: Costs of cancer care are increasing worldwide, and sustainability of cancer burden is critical. In this study, the economic impact of rectal cancer on the Italian healthcare system, measured as public healthcare expenditure related to investigation and treatment of rectal cancer patients is estimated. A cross-sectional cohort of 9358 rectal cancer patients is linked, on an individual basis, to claims associated to rectal cancer diagnosis and treatments. Costs refer mainly to years 2010&ndash, 2011 and are estimated by phase of care, as healthcare needs vary along the care pathway: diagnostic procedures are mainly provided in the first year, surveillance procedures are addressed to chronically ill patients, and end-of-life procedures are given in the terminal status. Clinical approaches and corresponding costs are specific by cancer type and vary by phase of care, stage at diagnosis, and age. Surgery is undertaken by the great majority of patients. Thus, hospitalization is the main cost driver. The evidence produced can be used to improve planning and allocation of healthcare resources. In particular, early diagnosis of rectal cancer is a gain in healthcare budget. Policies raising spreading of and adherence to screening plans, above all when addressed to people living in Southern Italy, should be strongly encouraged.
Published: 2021

10. Changes in life expectancy for cancer patients over time since diagnosis

Author: Botta, L., Dal Maso, L., Guzzinati, S., Panato, C., Gatta, G., Trama, A., Rugge, M., Tagliabue, G., Casella, C., Caruso, B., Michiara, M., Ferretti, S., Sensi, F., Tumino, R., Toffolutti, F., Russo, A. G., Caiazzo, A. L., Mangone, L., Mazzucco, W., Iacovacci, S., Ricci, P., Gola, G., Candela, G., Sardo, A. S., De Angelis, R., Buzzoni, C., Capocaccia, R., AIRTUM Working Group, Botta, Laura, Dal Maso, Luigino, Guzzinati, Stefano, Panato, Chiara, Gatta, Gemma, Trama, Annalisa, Rugge, Massimo, Tagliabue, Giovanna, Casella, Claudia, Caruso, Bianca, Michiara, Maria, Ferretti, Stefano, Sensi, Flavio, Tumino, Rosario, Toffolutti, Federica, Giampiero Russo, Antonio, Luisa Caiazzo, Anna, Mangone, Lucia, Mazzucco, Walter, Iacovacci, Silvia, Ricci, Paolo, Gola, Gemma, Candela, Giuseppa, Sutera Sardo, Antonella, De Angelis, Roberta, Buzzoni, Carlotta, and Capocaccia, Riccardo
Subjects: 0301 basic medicine, Pediatrics, medicine.medical_specialty, cancer survivor, Life expectancy, Cancer survivors, Population, YLL, years of life lost, (ICD-O-3), international classification of diseases for oncology, third revision, Socio-culturale, Life expectancy, Population-based cancer registry, Relative survival, Cancer, Cancer survivors, Italy, Settore MED/42 - Igiene Generale E Applicata, Relative survival, 03 medical and health sciences, 0302 clinical medicine, Health care, Medicine, education, lcsh:Science (General), Population-based cancer registry, Thyroid cancer, Cancer, RS, relative survival, education.field_of_study, lcsh:R5-920, Multidisciplinary, business.industry, Absolute risk reduction, medicine.disease, LE, life expectancy, NHL, non-Hodgkin lymphoma, 030104 developmental biology, Years of potential life lost, Italy, ISTAT, national institute of statistics, 030220 oncology & carcinogenesis, (ICD-10), international classification of diseases tenth revision, Original Article, business, lcsh:Medicine (General), lcsh:Q1-390
Abstract: Highlights • Research question: how cancer impacts on LE changes during patients’ entire life • LE increased in patients surviving the first years and decreasing thereafter. • Patients’ LE in the end approached but seldom reached the general population’s LE. • This method describes when cancer survivors’ excess risk of death became negligible. • Life expectancy indicator is easy to be understood and interpreted by patients., Graphical abstract, The aims of this study were to provide life expectancy (LE) estimates of cancer patients at diagnosis and LE changes over time since diagnosis to describe the impact of cancer during patients' entire lives. Cancer patients' LE was calculated by standard period life table methodology using the relative survival of Italian patients diagnosed in population-based cancer registries in 1985–2011 with follow-up to 2013. Data were smoothed using a polynomial model and years of life lost (YLL) were calculated as the difference between patients' LE and that of the age- and sex-matched general population. The YLL at diagnosis was highest at the youngest age at diagnosis, steadily decreasing thereafter. For patients diagnosed at age 45 years, the YLL was above 20 for lung and ovarian cancers and below 6 for thyroid cancer in women and melanoma in men. LE progressively increased in patients surviving the first years, decreasing thereafter, to approach that of the general population. YLL in the long run mainly depends on attained age. Providing quantitative data is essential to better define clinical follow-up and plan health care resource allocation. These results help assess when the excess risk of death from tumour becomes negligible in cancer survivors.
Published: 2019

11. Decline in the incidence of colorectal cancer and the associated mortality in young Italian adults

Author: Zorzi M., Cavestro G. M., Guzzinati S., Dal Maso L., Rugge M., Mazzoleni G., Morrone G., Caputo E., Galasso R., Citarella A., Sampietro G., Magoni M., Cavalieri D'Oro L., Ardizzone A., D'Argenzio A., Sciacca S., Pisani S., Ricci P., Giorno A., Ferretti S., Palma F., Serraino D., Iacovacci S., Quarta F., Filiberti R. A., Vitarelli S., Russo A. G., Carrozzi G., D'Orsi G., Fusco M., Sini G. M., Vitale F., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A. L., Cesaraccio R., Madeddu A., Fanetti A. C., Minerba S., Caldarella A., Candela G., Piffer S., Stracci F., Tagliabue G., Tolin M., Brustolin A., Castelli M., Zorzi M., Cavestro G.M., Guzzinati S., Dal Maso L., Rugge M., Mazzoleni G., Morrone G., Caputo E., Galasso R., Citarella A., Sampietro G., Magoni M., Cavalieri D'Oro L., Ardizzone A., D'Argenzio A., Sciacca S., Pisani S., Ricci P., Giorno A., Ferretti S., Palma F., Serraino D., Iacovacci S., Quarta F., Filiberti R.A., Vitarelli S., Russo A.G., Carrozzi G., D'Orsi G., Fusco M., Sini G.M., Vitale F., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A.L., Cesaraccio R., Madeddu A., Fanetti A.C., Minerba S., Caldarella A., Candela G., Piffer S., Stracci F., Tagliabue G., Tolin M., Brustolin A., Castelli M., Zorzi, M., Cavestro, G. M., Guzzinati, S., Dal Maso, L., and Rugge, M
Subjects: 0301 basic medicine, Colon, Population, Socio-culturale, colorectal cancer, colorectal cancer screening, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Epidemiology of cancer, Medicine, Humans, Risk factor, education, education.field_of_study, cancer epidemiology, Colorectal cancer, colorectal cancer screening, business.industry, Incidence (epidemiology), Mortality rate, screening, Incidence, Gastroenterology, Cancer, medicine.disease, Obesity, Annual Percent Change, Europe, 030104 developmental biology, Italy, 030211 gastroenterology & hepatology, epidemiology, business, Colorectal Neoplasms, Demography, cancer epidemiology, SEER Program
Abstract: Objective The incidence of colorectal cancer (CRC) declines among subjects aged 50 years and above. An opposite trend appears among younger adults. In Europe, data on CRC incidence among younger adults are lacking. We therefore aimed to analyse European trends in CRC incidence and mortality in subjects younger than 50 years. Design Data on age-related CRC incidence and mortality between 1990 and 2016 were retrieved from national and regional cancer registries. Trends were analysed by Joinpoint regression and expressed as annual percent change. Results We retrieved data on 143.7 million people aged 20–49 years from 20 European countries. Of them, 187 918 (0.13%) were diagnosed with CRC. On average, CRC incidence increased with 7.9% per year among subjects aged 20–29 years from 2004 to 2016. The increase in the age group of 30–39 years was 4.9% per year from 2005 to 2016, the increase in the age group of 40–49 years was 1.6% per year from 2004 to 2016. This increase started earliest in subjects aged 20–29 years, and 10–20 years later in those aged 30–39 and 40–49 years. This is consistent with an age-cohort phenomenon. Although in most European countries the CRC incidence had risen, some heterogeneity was found between countries. CRC mortality did not significantly change among the youngest adults, but decreased with 1.1%per year between 1990 and 2016 and 2.4% per year between 1990 and 2009 among those aged 30–39 years and 40–49 years, respectively. Conclusion CRC incidence rises among young adults in Europe. The cause for this trend needs to be elucidated. Clinicians should be aware of this trend. If the trend continues, screening guidelines may need to be reconsidered.
Published: 2020

12. RISK OF HEMOLYMPHOPOIETIC NEOPLASM BEFORE AND AFTER THYROID CANCER. A POPULATION‐BASED STUDY IN ITALY, 1998‐2012

Author: Mattioli, V., primary, Crocetti, E., additional, Dal Maso, L., additional, Buzzoni, C., additional, Franceschi, S., additional, Serraino, D., additional, Vaccarella, S., additional, Ferretti, S., additional, Busco, S., additional, Fedeli, U., additional, Varvarà, M., additional, Falcini, F., additional, Zorzi, M., additional, Carrozzi, G., additional, Mazzucco, W., additional, Gasparotti, C., additional, Iacovacci, S., additional, Toffolutti, F., additional, Cavallo, R., additional, Stracci, F., additional, Russo, A. G., additional, Caldarella, A., additional, Rosso, S., additional, Musolino, A., additional, Mangone, L., additional, Casella, C., additional, Fusco, M., additional, Tagliabue, G., additional, Piras, D., additional, Tumino, R., additional, Guarda, L., additional, Dinaro, Y. M., additional, Piffer, S., additional, Pinna, P., additional, Mazzoleni, G., additional, and Fanetti, A. C., additional
Published: 2021
Full Text: View/download PDF

13. Diabetes: awareness and management. Data of Passi and Passi d’Argento surveillance in Lazio, Italy

Author: Paradiso, F, primary, Agosti, G, additional, Prencipe, G P, additional, Trinito, M O, additional, Iacovacci, S, additional, Contoli, B, additional, Minardi, V, additional, and Masocco, M, additional
Published: 2020
Full Text: View/download PDF

14. Novel and recurrent mutations in the integrin beta 4 subunit gene causing lethal junctional epidermolysis bullosa with pyloric atresia

Author: Iacovacci, S., Cicuzza, S., Odorisio, T., Silvestri, E., Kayserili, H., Zambruno, G., Puddu, P., and DʼAlessio, M.
Published: 2003

15. Cancer incidence and mortality trends from 2003 to 2014 in Italy

Author: Buzzoni, Carlotta, primary, Crocetti, Emanuele, additional, Guzzinati, Stefano, additional, Dal Maso, Luigino, additional, Francisci, Silvia, additional, Mazzoleni, G, additional, Ferrara, MA, additional, Caputo, E, additional, Coviello, E, additional, Galasso, R, additional, Citarella, A, additional, Sampietro, G, additional, Magoni, M, additional, Ardizzone, A, additional, D’Argenzio, A, additional, Sutera Sardo, A, additional, Giorno, A, additional, La Greca, G, additional, Ricci, P, additional, Ferretti, S, additional, Palma, F, additional, Serraino, D, additional, Iacovacci, S, additional, Melcarne, A, additional, Puppo, A, additional, Sciacca, S, additional, Russo, AG, additional, Caruso, Bianca, additional, Cavalieri d’Oro, L, additional, D’Orsi, G, additional, Fusco, M, additional, Usala, M, additional, Vitale, F, additional, Cusimano, R, additional, Michiara, M, additional, Boschetti, L, additional, Chiaranda, G, additional, Rosso, S, additional, Tumino, R, additional, Mangone, L, additional, Valenti Clemente, S, additional, Falcini, F, additional, Caiazzo, AL, additional, Cesaraccio, R, additional, Tisano, F, additional, Fanetti, AC, additional, Minerba, S, additional, Caldarella, A, additional, Candela, G, additional, Piffer, S, additional, Cania, A, additional, Castelli, M, additional, Pisani, M, additional, Tagliabue, G, additional, Bovo, E, additional, and Brustolin, A, additional
Published: 2019
Full Text: View/download PDF

16. Trends of colorectal cancer incidence and mortality rates from 2003 to 2014 in Italy

Author: Zorzi, Manuel, primary, Dal Maso, Luigino, additional, Francisci, Silvia, additional, Buzzoni, Carlotta, additional, Rugge, Massimo, additional, Guzzinati, Stefano, additional, Mazzoleni, G., additional, Coviello, E., additional, Galasso, R., additional, Sampietro, G., additional, Magoni, M., additional, Ardizzone, A., additional, D‘Argenzio, A., additional, Sutera Sardo, A., additional, Giorno, A., additional, La Greca, G., additional, Ricci, P., additional, Ferretti, S., additional, Palma, F., additional, Serraino, D., additional, Iacovacci, S., additional, Melcarne, A., additional, Puppo, A., additional, Sciacca, S., additional, Russo, A.G., additional, Caruso, B., additional, Cavalieri d’Oro, L., additional, D‘Orsi, G., additional, Fusco, M., additional, Usala, M., additional, Vitale, F., additional, Cusimano, R., additional, Michiara, M., additional, Boschetti, L., additional, Chiaranda, G., additional, Rosso, S., additional, Tumino, R., additional, Mangone, L., additional, Falcini, F., additional, Caiazzo, A.L., additional, Cesaraccio, R., additional, Tisano, F., additional, Fanetti, A.C., additional, Minerba, S., additional, Caldarella, A., additional, Candela, G., additional, Piffer, S., additional, Cania, A., additional, Castelli, M., additional, Pisani, M., additional, Tagliabue, G., additional, Bovo, E., additional, and Brustolin, A., additional
Published: 2019
Full Text: View/download PDF

17. Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact

Author: VALLI M. B, SERAFINO A, CREMA A, BERTOLINI L, LANZILLI G, BOSMAN C, IACOVACCI S, GIUNTA S, PONZETTO A, CARLONI G., CLEMENTI , MASSIMO, VALLI M., B, Serafino, A, Crema, A, Bertolini, L, Lanzilli, G, Bosman, C, Iacovacci, S, Giunta, S, Ponzetto, A, Clementi, Massimo, and Carloni, G.
Published: 2006

18. Socioeconomic inequity in Lazio: trend analysis of FOBT execution using Passi surveillance data

Author: Trinito, MO, primary, Lancia, A, additional, Iacovacci, S, additional, Pettinicchio, V, additional, Trivellini, R, additional, Follacchio, D, additional, Boggi, R, additional, Fovi De Ruggiero, G, additional, Lucaroni, F, additional, and Braggion, M, additional
Published: 2015
Full Text: View/download PDF

19. Passi surveillance and overweight prevalence trend for age and socioeconomic level in Lazio region

Author: Pettinicchio, V, primary, Trinito, MO, additional, Lancia, A, additional, Iacovacci, S, additional, Ruscio, V, additional, Coia, M, additional, Micali, O, additional, Corradi, S, additional, Verginelli, F, additional, and Braggion, M, additional
Published: 2015
Full Text: View/download PDF

20. Molecular characterization and dynamics of hepatitis c virus replication in human fetal hepatocytes infected in vitro

Author: IACOVACCI S., MANZIN A., BARCA S., SARGIACOMO M., SERAFINO A. L., VALLI M. B., MACIOCE G. P., HASSAN H. J., PONZETTO A., PESCHLE C., CARLONI G., CLEMENTI , MASSIMO, Iacovacci, S., Manzin, A., Barca, S., Sargiacomo, M., Serafino, A. L., Valli, M. B., Macioce, G. P., Hassan, H. J., Ponzetto, A., Clementi, Massimo, Peschle, C., and Carloni, G.
Published: 1997

21. Low cell dosage of lymphoblastoid human cell lines EBV+ is associated to chronic hepatitis in a minority of inoculated Nu/Nu mice

Author: Bertolini L. 1, Iacovacci S. 2, Bosman C. 3, Carloni G. 4, Monaco V. 5, Bangrazi C. 6, Serafino A. 7, Gualandi G. 8, Prantera G. 9, and Fruscalzo A. 10
Subjects: athymic mice, EBV, liver lesion
Abstract: It has been suggested that an atypical course of primary infection by EBV and the reactivation of EBV infection in transplanted patients may induce hepatitis. We explored the possibility to dissect the infectious activity from the ability to promote B lymphocyte proliferation in vivo by injecting in nu/nu mice a low number (2 x 10(6)-0.05 x 10(6)) of cells from CE a normal human bone marrow-derived B cell line. This line carries an endogenous EBV in episomal and linear forms. Twenty nu/nu mice were inoculated subcutaneously with the B cell line CE and a matched group with the cell line RAG obtained by EBV in vitro infection of normal human peripheral blood. The mice injected with the CE line did not develop a lymphoproliferative disease, but 5 of them displayed typical histopathological lesions of chronic hepatitis without involvement of other organs. Similar results were obtained in 2 out of 20 animals in the RAG group. A close association between liver lesions and a previous EBV infection, by putative circulating B lymphoblastoid cells releasing their EBV, was established by PCR and by in situ hybridization with BamHI "W" DNA probe. This latter probe detected the presence of about 15% of positive cells only in affected livers. In addition, the rare detection in some hepatocytes of "A" type Cowdry bodies would suggest the occurrence of continuous EBV replication although at a very low level. These data show that we succeeded in dissecting the infectious from the proliferative activity of the endogenous EBV carrier CE cell line. This provides in addition a promising model for chronic EBV-associated hepatitis.
Published: 2001

22. Evidence for Epstein Barr Virus (EBV) fusion with a human hepatoma cell line (Li7A) via a receptor phenotipically distinct from CR2

Author: Antonella Lisi, Lanzilli, G., Pozzi, D., Santoro, N., Iacovacci, S., Carloni, G., and Grimaldi, S.
Published: 1993

23. Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected in vitro.

Author: Iacovacci, S, primary
Published: 1997
Full Text: View/download PDF

24. Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infectedin vitro

Author: Iacovacci, S, primary, Manzin, A, additional, Barca, S, additional, Sargiacomo, M, additional, Serafino, A, additional, Valli, M B, additional, Macioce, G, additional, Hassan, H J, additional, Ponzetto, A, additional, Clementi, M, additional, Peschle, C, additional, and Carloni, G, additional
Published: 1997
Full Text: View/download PDF

25. Quantitation of hepatitis C virus RNA production in two human bone marrow-derived B-cell lines infected in vitro

Author: Iacovacci, S., primary, Bertolini, L., additional, Manzin, A., additional, Valli, M.B., additional, Battaglia, M., additional, Ponzetto, A., additional, Clementi, M., additional, and Carloni, G., additional
Published: 1997
Full Text: View/download PDF

26. Detection of a 5′ UTR variation in the HCV genome after long-term in vitro infection

Author: Valli, M.B., primary, Bertolini, L., additional, Iacovacci, S., additional, Ponzetto, A., additional, and Carloni, G., additional
Published: 1995
Full Text: View/download PDF

27. Fusion of EBV with the surface of receptor-negative human hepatoma cell line Li7A permits virus penetration and infection

Author: Lisi, A., primary, Pozzi, D., additional, Carloni, G., additional, Da Villa, G., additional, Iacovacci, S., additional, Valli, M.B., additional, and Grimaldi, S., additional
Published: 1995
Full Text: View/download PDF

28. The human bone-marrow-derived B-cell line CE, susceptible to hepatitis C virus infection

Author: Bertolini, L., primary, Iacovacci, S., additional, Ponzetto, A., additional, Gorini, G., additional, Battaglia, M., additional, and Carloni, G., additional
Published: 1993
Full Text: View/download PDF

29. Early steps in fusion between epstein-barr virus and a human hepatoma cell line (Li7A)

Author: Lisi, A., primary, Pozzi, D., additional, Iacovacci, S., additional, Carloni, G., additional, Lanzilli, G., additional, De Ros, I., additional, Ravagnan, G., additional, and Grimaldi, S., additional
Published: 1993
Full Text: View/download PDF

30. Replication and multiplication of hepatitis C virus genome in human foetal liver cells

Author: Iacovacci, S., primary, Sargiacomo, M., additional, Parolini, I., additional, Ponzetto, A., additional, Peschle, C., additional, and Carloni, G., additional
Published: 1993
Full Text: View/download PDF

31. Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort

Author: Francesco Cuccaro, Maria Francesca Vitale, Marine Castaing, Simona Carone, Lorenza Boschetti, Salvatore Pisani, Rosa Filiberti, Silvano Piffer, Walter Mazzucco, Fabrizio Stracci, Giovanna Tagliabue, Giuseppe Sampietro, Antonino Ardizzone, Maurizio Castelli, Cinzia Gasparotti, Gianfranco Manneschi, Giancarlo D'Orsi, Andrea Tittarelli, Giulio Barigelletti, Paolo Contiero, Angelo D'Argenzio, Laura Botta, Gemma Gatta, Cinzia Storchi, Luca Cavalieri D'Oro, Anna Melcarne, Lucia Mangone, Alice Bernasconi, Rosario Tumino, Stefano Guzzinati, Fabio Savoia, Paola Ballotari, Giuseppa Candela, Cristiana Pascucci, Fabio Falcini, Anita Andreano, Annalisa Trama, Claudia Cirilli, Silvia Iacovacci, A.C. Fanetti, Trama, A, Tittarelli, A, Barigelletti, G, Botta, L, Gatta, G, Tagliabue, G, Contiero, P, Guzzinati, S, Andreano, A, Manneschi, G, Falcini, F, Castaing, M, Filiberti, R, Gasparotti, C, Cirilli, C, Mazzucco, W, Mangone, L, Iacovacci, S, Vitale, M, Stracci, F, Piffer, S, Tumino, R, Carone, S, Sampietro, G, Melcarne, A, Ballotari, P, Boschetti, L, Pisani, S, Cavalieri D'Oro, L, Cuccaro, F, D'Argenzio, A, D'Orsi, G, Fanetti, A, Ardizzone, A, Candela, G, Savoia, F, Pascucci, C, Castelli, M, Storchi, C, Bernasconi, A, Trama A., Tittarelli A., Barigelletti G., Botta L., Gatta G., Tagliabue G., Contiero P., Guzzinati S., Andreano A., Manneschi G., Falcini F., Castaing M., Filiberti R.A., Gasparotti C., Cirilli C., Mazzucco W., Mangone L., Iacovacci S., Vitale M.F., Stracci F., Piffer S., Tumino R., Carone S., Sampietro G., Melcarne A., Ballotari P., Boschetti L., Pisani S., Cavalieri D'Oro L., Cuccaro F., D'Argenzio A., D'Orsi G., Fanetti A.C., Ardizzone A., Candela G., Savoia F., Pascucci C., Castelli M., Storchi C., and Bernasconi A.
Subjects: Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, Colorectal cancer, cancer survivor, Population, Breast Neoplasms, Settore MED/42 - Igiene Generale E Applicata, Prostate cancer, Breast cancer, Risk Factors, Internal medicine, Neoplasms, follow-up, Medicine, Humans, cancer survivors, Cumulative incidence, adolescents, education, Lung cancer, Retrospective Studies, education.field_of_study, Bladder cancer, business.industry, Incidence, Cancer, registries, Neoplasms, Second Primary, medicine.disease, humanities, registrie, adolescents, cancer survivors, follow-up, registries, young adult, young adult, Female, business
Abstract: Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scarce. This study assessed the risk of subsequent malignant neoplasms (SMNs) to identify the most common SMNs to be considered in follow-up care. Methods: Population-based cancer registries retrospectively identified first primary tumors (between 1976 and 2013) and SMNs in AYAs (15-39years old at their cancer diagnosis). AYA cancer survivors were those alive at least 5years after their first cancer diagnosis. The excess risk of SMNs was measured as standardized incidence ratios (SIRs) and absolute excess risk together with the cumulative incidence of SMNs. Results: The cohort included 67,692 AYA cancer survivors. The excess risk of developing any SMN (SIR, 1.6; 95% confidence interval, 1.5-1.7) was 60%. The excess risk of SMNs was significantly high for survivors of lymphomas; cancers of the breast, thyroid, female genital tract, digestive organs, gonads, and urinary tract; and melanomas. The cumulative incidence of all SMNs in AYA cancer survivors within 25years of their first cancer diagnosis was approximately 10%. Subsequent tumors contributing to approximately 60% of all SMNs were breast cancer, colorectal cancer, corpus uteri cancer, and ovarian cancer in females and colorectal cancer, bladder cancer, prostate cancer, lung cancer, and lymphomas in males. Conclusions: These results highlight the need to personalize follow-up strategies for AYA cancer survivors.
Published: 2022

32. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study

Author: Laura Botta, Gemma Gatta, Riccardo Capocaccia, Charles Stiller, Adela Cañete, Luigino Dal Maso, Kaire Innos, Ana Mihor, Friederike Erdmann, Claudia Spix, Brigitte Lacour, Rafael Marcos-Gragera, Deirdre Murray, Silvia Rossi, Monika Hackl, Elizabeth Van Eycken, Nancy Van Damme, Zdravka Valerianova, Mario Sekerija, Vasos Scoutellas, Anna Demetriou, Ladislav Dušek, Denisa Krejci, Hans Storm, Margit Mägi, Keiu Paapsi, Nea Malila, Janne Pitkäniemi, Valerie Jooste, Jacqueline Clavel, Claire Poulalhon, Emmanuel Desandes, Alain Monnereau, Alexander Katalinic, Eleni Petridou, Georgios Markozannes, Miklos Garami, Helgi Birgisson, Paul M Walsh, Guido Mazzoleni, Fabio Vittadello, Francesco Cuccaro, Rocco Galasso, Giuseppe Sampietro, Stefano Rosso, Cinzia Gasparotto, Giovanni Maifredi, Margherita Ferrante, Antonina Torrisi, Antonella Sutera Sardo, Maria Letizia Gambino, Monica Lanzoni, Paola Ballotari, Erica Giacomazzi, Stefano Ferretti, Adele Caldarella, Gianfranco Manneschi, Milena Sant, Paolo Baili, Franco Berrino, Annalisa Trama, Roberto Lillini, Alice Bernasconi, Simone Bonfarnuzzo, Claudia Vener, Fabio Didonè, Paolo Lasalvia, Giulia Del Monego, Lucia Buratti, Diego Serraino, Martina Taborelli, Roberta De Angelis, Elena Demuru, Corrado Di Benedetto, Mariano Santaquilani, Serenella Venanzi, Marco Tallon, Luca Boni, Silvia Iacovacci, Antonio Giampiero Russo, Federico Gervasi, Gianbattista Spagnoli, Luca Cavalieri d'Oro, Mario Fusco, Maria Francesca Vitale, Mario Usala, Francesco Vitale, Maria Michiara, Giorgio Chiranda, Carlotta Sacerdote, Milena Maule, Giuseppe Cascone, Eugenia Spata, Lucia Mangone, Fabio Falcini, Rossella Cavallo, Daniela Piras, Ylenia Dinaro, Marine Castaing, Anna Clara Fanetti, Sante Minerba, Giuseppina Candela, Tiziana Scuderi, Roberto Vito Rizzello, Fabrizio Stracci, Giovanna Tagliabue, Massimo Rugge, Angelita Brustolin, Santa Pildava, Giedre Smailyte, Miriam Azzopardi, Tom Børge Johannesen, Joanna Didkowska, Urszula Wojciechowska, Magdalena Bielska-Lasota, Ana Pais, Ana Maria Ferreira, Maria José Bento, Ana Miranda, Chakameh Safaei Diba, Vesna Zadnik, Tina Zagar, Carmen Sánchez-Contador Escudero, Paula Franch Sureda, Arantza Lopez de Munain, Marta De-La-Cruz, Marìa Dolores Rojas, Araceli Aleman, Ana Vizcaino, Fernando Almela, Arantza Sanvisens, Maria Josè Sanchez, Maria Dolores Chirlaque, Antonia Sanchez-Gil, Marcela Guevara, Eva Ardanaz, Adela Cañete-Nieto, Rafael Peris-Bonet, Jaume Galceran, Maria Carulla, Claudia Kuehni, Shelagh Redmond, Otto Visser, Henrike Karim-Kos, Sarah Stevens, Anna Gavin, David Morrison, Dyfed Wyn Huws, Botta, L, Gatta, G, Capocaccia, R, Stiller, C, Canete, A, Dal Maso, L, Innos, K, Mihor, A, Erdmann, F, Spix, C, Lacour, B, Marcos-Gragera, R, Murray, D, Rossi, S, Hackl, M, Van Eycken, E, Van Damme, N, Valerianova, Z, Sekerija, M, Scoutellas, V, Demetriou, A, Dusek, L, Krejci, D, Storm, H, Magi, M, Paapsi, K, Malila, N, Pitkaniemi, J, Jooste, V, Clavel, J, Poulalhon, C, Desandes, E, Monnereau, A, Katalinic, A, Petridou, E, Markozannes, G, Garami, M, Birgisson, H, Walsh, P, Mazzoleni, G, Vittadello, F, Cuccaro, F, Galasso, R, Sampietro, G, Rosso, S, Gasparotto, C, Maifredi, G, Ferrante, M, Torrisi, A, Sutera Sardo, A, Gambino, M, Lanzoni, M, Ballotari, P, Giacomazzi, E, Ferretti, S, Caldarella, A, Manneschi, G, Sant, M, Baili, P, Berrino, F, Trama, A, Lillini, R, Bernasconi, A, Bonfarnuzzo, S, Vener, C, Didone, F, Lasalvia, P, Del Monego, G, Buratti, L, Serraino, D, Taborelli, M, De Angelis, R, Demuru, E, Di Benedetto, C, Santaquilani, M, Venanzi, S, Tallon, M, Boni, L, Iacovacci, S, Russo, A, Gervasi, F, Spagnoli, G, Cavalieri d'Oro, L, Fusco, M, Vitale, M, Usala, M, Vitale, F, Michiara, M, Chiranda, G, Sacerdote, C, Maule, M, Cascone, G, Spata, E, Mangone, L, Falcini, F, Cavallo, R, Piras, D, Dinaro, Y, Castaing, M, Fanetti, A, Minerba, S, Candela, G, Scuderi, T, Rizzello, R, Stracci, F, Tagliabue, G, Rugge, M, Brustolin, A, Pildava, S, Smailyte, G, Azzopardi, M, Johannesen, T, Didkowska, J, Wojciechowska, U, Bielska-Lasota, M, Pais, A, Ferreira, A, Bento, M, Miranda, A, Safaei Diba, C, Zadnik, V, Zagar, T, Sanchez-Contador Escudero, C, Franch Sureda, P, Lopez de Munain, A, De-La-Cruz, M, Rojas, M, Aleman, A, Vizcaino, A, Almela, F, Sanvisens, A, Sanchez, M, Chirlaque, M, Sanchez-Gil, A, Guevara, M, Ardanaz, E, Canete-Nieto, A, Peris-Bonet, R, Galceran, J, Carulla, M, Kuehni, C, Redmond, S, Visser, O, Karim-Kos, H, Stevens, S, Gavin, A, Morrison, D, and Huws, D
Subjects: Retinal Neoplasms, Retinoblastoma, Bone Neoplasms, Sarcoma, Ewing, EUROCARE-6, survival, Burkitt Lymphoma, population-based cancer registrie, Europe, Oncology, Humans, cure fraction, childhood cancer, EUROCARE, Child, chidlhood cancer
Abstract: Background: The EUROCARE-5 study revealed disparities in childhood cancer survival among European countries, giving rise to important initiatives across Europe to reduce the gap. Extending its representativeness through increased coverage of eastern European countries, the EUROCARE-6 study aimed to update survival progress across countries and years of diagnosis and provide new analytical perspectives on estimates of long-term survival and the cured fraction of patients with childhood cancer. Methods: In this population-based study, we analysed 135 847 children (aged 0–14 years) diagnosed during 2000–13 and followed up to the end of 2014, recruited from 80 population-based cancer registries in 31 European countries. We calculated age-adjusted 5-year survival differences by country and over time using period analysis, for all cancers combined and for major cancer types. We applied a variant of standard mixture cure models for survival data to estimate the cure fraction of patients by childhood cancer and to estimate projected 15-year survival. Findings: 5-year survival for all childhood cancer combined in Europe in 2010–14 was 81% (95% CI 81–82), showing an increase of three percentage points compared with 2004–06. Significant progress over time was observed for almost all cancers. Survival remained stable for osteosarcomas, Ewing sarcoma, Burkitt lymphoma, non-Hodgkin lymphomas, and rhabdomyoscarcomas. For all cancers combined, inequalities still persisted among European countries (with age-adjusted 5-year survival ranging from 71% [95% CI 60–79] to 87% [77–93]). The 15-year survival projection for all patients with childhood cancer diagnosed in 2010–13 was 78%. We estimated the yearly long-term mortality rate due to causes other than the diagnosed cancer to be around 2 per 1000 patients for all childhood cancer combined, but to approach zero for retinoblastoma. The cure fraction for patients with childhood cancer increased over time from 74% (95% CI 73–75) in 1998–2001 to 80% (79–81) in 2010–13. In the latter cohort, the cure fraction rate ranged from 99% (95% CI 74–100) for retinoblastoma to 60% (58–63) for CNS tumours and reached 90% (95% CI 87–93) for lymphoid leukaemia and 70% (67–73) for acute myeloid leukaemia. Interpretation: Childhood cancer survival is increasing over time in Europe but there are still some differences among countries. Regular monitoring of childhood cancer survival and estimation of the cure fraction through population-based registry data are crucial for evaluating advances in paediatric cancer care. Funding: European Commission.
Published: 2022

33. Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998–2012

Author: Emanuele Crocetti, Veronica Mattioli, Carlotta Buzzoni, Silvia Franceschi, Diego Serraino, Salvatore Vaccarella, Stefano Ferretti, Susanna Busco, Ugo Fedeli, Massimo Varvarà, Fabio Falcini, Manuel Zorzi, Giuliano Carrozzi, Walter Mazzucco, Cinzia Gasparotti, Silvia Iacovacci, Federica Toffolutti, Rossella Cavallo, Fabrizio Stracci, Antonio G. Russo, Adele Caldarella, Stefano Rosso, Antonino Musolino, Lucia Mangone, Claudia Casella, Mario Fusco, Giovanna Tagliabue, Daniela Piras, Rosario Tumino, Linda Guarda, Ylenia M. Dinaro, Silvano Piffer, Pasquala Pinna, Guido Mazzoleni, Anna C. Fanetti, Luigino Dal Maso, for AIRTUM working group, Crocetti E., Mattioli V., Buzzoni C., Franceschi S., Serraino D., Vaccarella S., Ferretti S., Busco S., Fedeli U., Varvara M., Falcini F., Zorzi M., Carrozzi G., Mazzucco W., Gasparotti C., Iacovacci S., Toffolutti F., Cavallo R., Stracci F., Russo A.G., Caldarella A., Rosso S., Musolino A., Mangone L., Casella C., Fusco M., Tagliabue G., Piras D., Tumino R., Guarda L., Dinaro Y.M., Piffer S., Pinna P., Mazzoleni G., Fanetti A.C., and Dal Maso L.
Subjects: Male, Oncology, Cancer Research, medicine.medical_specialty, population-based cancer registries, Population, Socio-culturale, Settore MED/42 - Igiene Generale E Applicata, History, 21st Century, Cohort Studies, Risk Factors, Prostate, Internal medicine, population‐based cancer registries, medicine, thyroid cancer, Humans, cancer survivors, Radiology, Nuclear Medicine and imaging, Registries, Thyroid Neoplasms, Overdiagnosis, education, Thyroid cancer, Research Articles, RC254-282, Italy, relative risk, second primary cancer, education.field_of_study, cancer survivors, Italy, population-based cancer registries, relative risk, second primary cancer, thyroid cancer, business.industry, Incidence, Incidence (epidemiology), Thyroid, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Cancer, Neoplasms, Second Primary, History, 20th Century, medicine.disease, medicine.anatomical_structure, Relative risk, Female, business, Cancer Prevention, Research Article
Abstract: Background The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC. Methods We analyzed two population‐based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population‐based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer. Results A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12–1.21) for SPC in TC patients, though no increase was shown for people with follicular (1.06) and medullary (0.95) TC. SPC with significantly increased SIRs was bone/soft tissue (2.0), breast (1.2), prostate (1.4), kidney (2.2), and hemolymphopoietic (1.4) cancers. The overall SIR for TC as a SPC was 1.49 (95% CI: 1.42–1.55), similar for all TC subtypes, and it was significantly increased for people diagnosed with head and neck (2.1), colon–rectum (1.4), lung (1.8), melanoma (2.0), bone/soft tissue (2.8), breast (1.3), corpus uteri (1.4), prostate (1.5), kidney (3.2), central nervous system (2.3), and hemolymphopoietic (1.8) cancers. Conclusions The increased risk of TC after many other neoplasms and of few SPC after TC questions the best way to follow‐up cancer patients, avoiding overdiagnosis and overtreatment for TC and, possibly, for other malignancies., This is the first study able to calculate population‐based risk of thyroid cancers as a first or second tumor separately for different thyroid cancer histological types (i.e., follicular, medullary, and poorly differentiated). In a context of a large proportion of thyroid cancer cases due to overdiagnosis, the findings of the present study may help to more focused primary prevention and surveillance for side effects of treatments, thus avoiding overtreatment, particularly among younger women.
Published: 2021

34. Cell to cell HCV transmission by chronically infected tofe cell line to human hepatoma cells 2.2.15

Author: Valli, M.B., Bertolipi, L., Ponzetto, A., Iacovacci, S., Falzetti, F., and Carloni, G.
Published: 1995
Full Text: View/download PDF

35. Cancer incidence and mortality trends from 2003 to 2014 in Italy

Author: Carlotta Buzzoni, Emanuele Crocetti, Stefano Guzzinati, Luigino Dal Maso, Silvia Francisci, G Mazzoleni, MA Ferrara, E Caputo, E Coviello, R Galasso, A Citarella, G Sampietro, M Magoni, A Ardizzone, A D’Argenzio, A Sutera Sardo, A Giorno, G La Greca, P Ricci, S Ferretti, F Palma, D Serraino, S Iacovacci, A Melcarne, A Puppo, S Sciacca, AG Russo, Bianca Caruso, L Cavalieri d’Oro, G D’Orsi, M Fusco, M Usala, F Vitale, R Cusimano, M Michiara, L Boschetti, G Chiaranda, S Rosso, R Tumino, L Mangone, S Valenti Clemente, F Falcini, AL Caiazzo, R Cesaraccio, F Tisano, AC Fanetti, S Minerba, A Caldarella, G Candela, S Piffer, A Cania, M Castelli, M Pisani, G Tagliabue, E Bovo, A Brustolin, Buzzoni C., Crocetti E., Guzzinati S., Dal Maso L., Francisci S., Mazzoleni G., Ferrara M.A., Caputo E., Coviello E., Galasso R., Citarella A., Sampietro G., Magoni M., Ardizzone A., D'Argenzio A., Sutera Sardo A., Giorno A., La Greca G., Ricci P., Ferretti S., Palma F., Serraino D., Iacovacci S., Melcarne A., Puppo A., Sciacca S., Russo A.G., Caruso B., Cavalieri d'Oro L., D'Orsi G., Fusco M., Usala M., Vitale F., Cusimano R., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A.L., Cesaraccio R., Tisano F., Fanetti A.C., Minerba S., Caldarella A., Candela G., Piffer S., Cania A., Castelli M., Pisani M., Tagliabue G., Bovo E., and Brustolin A.
Subjects: Registrie, Adult, Male, Cancer Research, Socio-culturale, cancer, Epidemiology and prevention, incidence, Italy, mortality, time trend, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, cancer, Medicine, Humans, 030212 general & internal medicine, Registries, Sex Distribution, Mortality trends, Aged, business.industry, Incidence (epidemiology), Incidence, Cancer, General Medicine, Middle Aged, medicine.disease, mortality, time trend, Oncology, Cancer incidence, Italy, 030220 oncology & carcinogenesis, Neoplasm, Epidemiology and prevention, Female, business, Human, Demography
Abstract: Objective: To evaluate short-term (2003–2014) cancer incidence and mortality trends in Italy. Methods: Italian Cancer Registries data, available in the AIRTUM database, from 17 out of 20 regions were used. The number of incident cases and deaths were estimated for those registries and those years with incomplete information. Age-standardized rates, overall and stratified by geographic area, region, sex, cancer site, and major age group, were computed. Time trends were expressed as annual percent change of rates. Results: In Italy, among males, incidence rates for all cancers showed during 2003–2014, a significant decrease (−0.9%/year), with stronger reductions in the northwest (−1.3%/year) and northeast (−2.0%/year since 2006) than in central (−0.7%/year) and southern (−0.4%/year) areas. Among females, a weak but significant overall reduction was detected (−0.1%/year), with a stronger decrease in the northwest (−0.5%/year). Incidence increased among women in the south (0.3%/year) of Italy. Mortality decreased in both sexes (−1.0%/year among males and −0.5%/year among females), but not in the south, where rates had a stable tendency. Conclusions: Incidence among males decreased, supported by trends for prostate, lung, colorectal, and urinary bladder cancers; among females the. The overall cancer incidence trend was stable, or even decreasing, in the northern and central areas and increasing in the southern areas, due to lung, thyroid, and melanoma rising trends. Study results provided information on the outcomes, in terms of cancer incidence and mortality, of primary and secondary prevention measures employed by regional health systems.
Published: 2019

36. Trends of colorectal cancer incidence and mortality rates from 2003 to 2014 in Italy

Author: Manuel Zorzi, Luigino Dal Maso, Silvia Francisci, Carlotta Buzzoni, Massimo Rugge, Stefano Guzzinati, G. Mazzoleni, E. Coviello, R. Galasso, G. Sampietro, M. Magoni, A. Ardizzone, A. D‘Argenzio, A. Sutera Sardo, A. Giorno, G. La Greca, P. Ricci, S. Ferretti, F. Palma, D. Serraino, S. Iacovacci, A. Melcarne, A. Puppo, S. Sciacca, A.G. Russo, B. Caruso, L. Cavalieri d’Oro, G. D‘Orsi, M. Fusco, M. Usala, F. Vitale, R. Cusimano, M. Michiara, L. Boschetti, G. Chiaranda, S. Rosso, R. Tumino, L. Mangone, F. Falcini, A.L. Caiazzo, R. Cesaraccio, F. Tisano, A.C. Fanetti, S. Minerba, A. Caldarella, G. Candela, S. Piffer, A. Cania, M. Castelli, M. Pisani, G. Tagliabue, E. Bovo, A. Brustolin, Zorzi M., Dal Maso L., Francisci S., Buzzoni C., Rugge M., Guzzinati S., Mazzoleni G., Coviello E., Galasso R., Sampietro G., Magoni M., Ardizzone A., D'Argenzio A., Sutera Sardo A., Giorno A., La Greca G., Ricci P., Ferretti S., Palma F., Serraino D., Iacovacci S., Melcarne A., Puppo A., Sciacca S., Russo A.G., Caruso B., Cavalieri d'Oro L., D'Orsi G., Fusco M., Usala M., Vitale F., Cusimano R., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Falcini F., Caiazzo A.L., Cesaraccio R., Tisano F., Fanetti A.C., Minerba S., Caldarella A., Candela G., Piffer S., Cania A., Castelli M., Pisani M., Tagliabue G., Bovo E., and Brustolin A.
Subjects: Male, Registrie, Cancer Research, Colorectal cancer, Socio-culturale, Colorectal Neoplasm, 03 medical and health sciences, 0302 clinical medicine, Age groups, medicine, Humans, Age Factor, Registries, Aged, Sex Characteristics, incidence, mortality, screening, business.industry, Incidence (epidemiology), Mortality rate, Age Factors, Cancer, General Medicine, Middle Aged, medicine.disease, Oncology, Italy, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Female, Colorectal Neoplasms, business, Demography, Sex characteristics, Human
Abstract: Objective: To evaluate the trends of colorectal cancer (CRC) incidence and mortality rates from 2003 to 2014 in Italy by age groups and regions. Methods: We used the data of 48 cancer registries from 17 Italian regions to estimate standardized incidence and mortality rates overall and by sex, age groups (Results: Incidence rates decreased from 104.3 (2003) to 89.9 × 100,000 (2014) in men and from 64.3 to 58.4 × 100,000 in women. Among men, incidence decreased during 2007–2010 (APC −4.0, 95% CI −6.0 to −1.9) and 2010–2014 (APC −0.7, 95% CI −1.4 to 0.0), while in women it linearly decreased during the whole period (APC −1.1, 95% CI −1.4 to −0.8). Mortality rates showed a linear reduction both in men (APC −0.7, 95% CI −1.0 to −0.3) and women (APC −0.9, 95% CI −1.2 to −0.6) and decreased respectively from 41.1 to 39.2 × 100,000 and from 24.6 to 23.1 × 100,000. In the 50- to 69-year-old range (screening target age), incidence showed a prescreening increase, followed by a peak after screening started, and a decline thereafter. Incidence and mortality rates significantly decreased in all areas but in the south and islands, where incidence increased and mortality remained stable. Conclusions: A renewed commitment by all regional health systems to invest in primary (i.e., lifestyle) and secondary (i.e., screening programs) prevention is of utmost importance.
Published: 2019

37. Neoadjuvant therapy for breast cancer

Author: Milena Sant, Lucia Mangone, Rosario Tumino, Rosa Filiberti, Paolo Giorgi Rossi, Giuliano Carrozzi, Walter Mazzucco, Pamela Mancuso, Giovanna Tagliabue, Silvia Iacovacci, Pamela Minicozzi, Mangone L., Mancuso P., Tagliabue G., Filiberti R.A., Carrozzi G., Iacovacci S., Mazzucco W., Tumino R., Minicozzi P., Sant M., and Giorgi Rossi P.
Subjects: Oncology, Adult, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Breast Neoplasms, Settore MED/42 - Igiene Generale E Applicata, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, Cancer screening, medicine, Biomarkers, Tumor, Odds Ratio, Mammography, Humans, 030212 general & internal medicine, neoadjuvant therapy, Neoadjuvant therapy, Triple-negative breast cancer, Tumor marker, Cancer staging, Aged, Neoplasm Staging, Aged, 80 and over, medicine.diagnostic_test, General Medicine, Middle Aged, medicine.disease, Combined Modality Therapy, Cancer registry, Treatment Outcome, 030220 oncology & carcinogenesis, Female, multidisciplinary
Abstract: Objective: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I–III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. Methods: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009–2013). Included were 3546 women aged Results: Only 8.2% of women (290 cases) underwent NT; the treatment decreases with increasing age (14.5% in age Conclusions: The use of NT in Italy is limited and variable. There are no signs of greater use in hospitals with more advanced care.
Published: 2019

38. Holographic approach to the light-by-light contribution to the muon (g-2)

Author: Luigi Cappiello, G. D’Ambrosio, M. Iacovacci, S. Mastroianni, M. Passera and G. Venanzoni, and Cappiello, Luigi
Subjects: Quantum chromodynamics, Physics, Particle physics, Anomalous magnetic dipole moment, 010308 nuclear & particles physics, QC1-999, Form factor (quantum field theory), Four-vector, 01 natural sciences, Scattering amplitude, Momento magnetico anomalo del muone, Modelli olografici della QCD, Pion, 0103 physical sciences, High Energy Physics::Experiment, Tensor, 010306 general physics, Pseudovector
Abstract: We discuss how holographic models of QCD are used to study the the hadronic light-by-light (HLbL) scattering amplitude contribution to the muon anomalous magnetic moment. After a brief description of the various models, we focus on a particular one, introduced by Hirn and Sanz, emphasizing the role it assigns to the pion, and the vector and-axial vector resonances. We review how the parameters of the model are fixed by imposing condition on the low energy and the deep Euclidean limit of two-point correlators of QCD vector and axial vector currents. We then focus on the evaluation of the three-point axial-vector-vector current correlator and the pion anomalous transition form factor to be used in the one-pion exchange HLbL diagram and study its asymptotic properties. Finally, we present preliminary results on the four vector current correlator that defines the Hadronic Light-by-Light tensor. We find that axial-vector resonances play an important rule in recovering the correct asymptotic behaviour predicted by QCD at large Euclidean momenta.
Published: 2020
Full Text: View/download PDF

39. Trans-Activation of Epidermal Growth Factor Receptor Gene by the Hepatitis B Virus X-Gene Product

Author: Massimo Clementi, Elena Alfani, Silvia Iacovacci, Massimo Levrero, Guido Carloni, Gioacchino Natoli, Patrizia Bagnarelli, Aldo Manzin, Maura Dandri, Stefano Menzo, Menzo, S, Clementi, Massimo, Alfani, E, Bagnarelli, P, Iacovacci, S, Manzin, A, Dandri, M, Natoli, G, Levrero, M, and Carloni, G.
Subjects: Chloramphenicol O-Acetyltransferase, Transcriptional Activation, Hepatitis B virus, Carcinoma, Hepatocellular, Recombinant Fusion Proteins, Genetic Vectors, Regulatory Sequences, Nucleic Acid, Biology, Transfection, Virus Replication, medicine.disease_cause, Gene product, Epidermal growth factor, Virology, Gene expression, Tumor Cells, Cultured, medicine, Humans, Viral Regulatory and Accessory Proteins, Promoter Regions, Genetic, Gene, Expression vector, Epidermal Growth Factor, Liver Neoplasms, Molecular biology, ErbB Receptors, Regulatory sequence, Trans-Activators
Abstract: The expression of the cellular gene coding for the epidermal growth factor (EGF) receptor (EGF-R) was assayed in the presence of hepatitis B virus (HBV) gene expression under different experimental conditions in human hepatoma-derived cells. First, transfection experiments of the well-differentiated HepG2 human hepatoma cell line using different expression vectors of the HBV X-region demonstrated that the X-gene product is capable of inducing EGF-R gene overexpression; in addition, by using a stable in vitro expression system for HBV, it was shown that EGF-R gene expression in these cells is greater than in the uninfected parent cells, and that this results in a three-fold increase in 125I-EGF binding. Finally, a CAT-expression assay was performed, indicating that regulatory regions of the EGF-R-gene are target sequences for X-protein trans-activation.
Published: 1993
Full Text: View/download PDF

40. Quantitation of hepatitis C virus RNA production in two human bone marrow-derived B-cell lines infected in vitro

Author: M. B. Valli, Luisa Bertolini, Guido Carloni, Massimo Battaglia, Massimo Clementi, Antonio Ponzetto, S. Iacovacci, Aldo Manzin, Iacovacci, S, Bertolini, L, Manzin, A, Valli, Mb, Battaglia, MARCO MARIA, Ponzetto, A, Clementi, Massimo, and Carloni, G.
Subjects: B-Lymphocytes, Hepatitis C virus, Immunology, RNA-dependent RNA polymerase, RNA, Bone Marrow Cells, Hepacivirus, Biology, Virus Replication, medicine.disease_cause, Polymerase Chain Reaction, Virology, Molecular biology, Reverse transcriptase, Virus, Cell Line, medicine.anatomical_structure, Bone Marrow, Cell culture, medicine, Humans, RNA, Viral, Nested polymerase chain reaction, B cell
Abstract: The ability of hepatitis C virus (HCV) to replicate in two B-cell lines, CE and TOFE, derived from bone marrow of healthy subjects was compared using qualitative and quantitative molecular methods. The presence of intracellular negative-stranded HCV RNA (replicative intermediate) was investigated by nested polymerase chain reaction (PCR) in the infected cultures at different times after infection. The amounts of positive-stranded HCV RNA (genomic RNA copies) synthesized and released from cells one week after in vitro infection were determined by competitive PCR after reverse transcription of viral RNA for the 5' viral untranslated region. In both cell lines, HCV RNA replication took place, but the TOFE cell line appeared to be a more efficient virus producer than the CE cell line. The TOFE cell line could be a valuable and reliable tool for basic and clinical HCV studies.
Published: 1997

41. Fertility and abortion: A population-based comparison between women with cancer and those in childbearing age.

Author: Maraschini A, Corsi Decenti E, Donati S, Francisci S, Lopez T, Amodio R, Bianconi F, Bovo E, Bruni R, Castaing M, Cirilli C, De Vincenzo RP, Furgiuele G, Guarda L, Iacovacci S, Mangone L, Mazzucco W, Melcarne A, Merlo E, Mian M, Sampietro G, Scambia G, Scuderi T, Sferrazza A, Stracci F, Torrisi A, Trojano V, Vitale MF, and Pierannunzio D
Subjects: Humans, Female, Adult, Pregnancy, Middle Aged, Italy epidemiology, Adolescent, Young Adult, Abortion, Spontaneous epidemiology, Pregnancy Complications, Neoplastic epidemiology, Registries statistics & numerical data, Abortion, Induced statistics & numerical data, Fertility, Neoplasms epidemiology
Abstract: Objectives: Concurrence of pregnancy and cancer diagnosis is increasingly frequent in Italy. The study aimed to compare women with pregnancy-associated cancers (PACs) to those of childbearing age, focusing on fertility, induced abortion, and miscarriage., Methods: The population-based study included women aged 15-49 years, both with and without PAC, who were residents in the area covered by the 19 participating Cancer Registries between 2003 and 2015 and identified by individual deterministic linkage with the Hospital Discharge Database., Results: Overall, 2,218,139 obstetrics hospitalizations occurred, covering delivery (75%), induced abortion (14%), and miscarriage (11%). Among 2409 women with PAC, 69% gave birth, 16% had an induced abortion and 15% a miscarriage. Compared with the reference population, the fertility rate in women with PACs was steadily lower (mean values 25.7/1000 vs 37.7/1000), while induced abortion (from 359/1000 - SRR 1.99, 95%CI 1.32-3.00 - in 2003 to 147/1000 - SRR 1.11, 95%CI 0.59-2.09 - in 2015) and miscarriage ratios exhibited a decreasing trend., Conclusion: These results are consistent with international literature and are probably due to advancements in diagnostic and therapeutic opportunities. This is the first Italian population-based study analysing fertility and pregnancy outcomes among women with PAC based on a reliable information on cancer diagnosis., Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Published: 2025
Full Text: View/download PDF

42. Le Pause Attive per la promozione dell’attività motoria: adesione degli istituti scolastici nel Lazio.

Author: Culasso M, Biscaglia L, Barca A, Cairella G, Iacovacci S, Livrieri S, Porta D, Saulle R, Brandimarte MA, Casagni L, Coia M, Corradi S, De Angelis F, De Sbrocchi C, Di Cesare F, Fabrizi E, Ferri M, Grandi M, Guida S, Luzza M, Maciocia L, Mascagna F, Michienzi F, Quartieri C, Rossetti L, Spaziani G, Vincenzo Spina ML, Tavani S, and Vallone A
Subjects: Humans, Child, Italy, School Health Services organization & administration, School Teachers, Exercise, Health Promotion methods, Schools, Sedentary Behavior
Abstract: Scuole che promuovono salute (Sps) is a model promoted by the World Health Organization and recognized at the European and national levels for promoting health and well-being at school. Pause Attive is an effective and evidence-based intervention to promote physical activity and reduce sedentary behaviour of children in the school setting. In the 2023-2024 school year, 348 schools joined the "Rete Lazio Sps" of which 99 joined the intervention Pause Attive for a total of 1.200 classes, more than 21.200 children involved and 1.500 teachers trained by health professionals of Asl. Pause Attive is a sustainable intervention for local health authority and effective in increasing movement and promoting attention and learning of children in the school setting.
Published: 2024
Full Text: View/download PDF

43. The descriptive epidemiology of melanoma in Italy has changed - for the better.

Author: Bucchi L, Mancini S, Crocetti E, Dal Maso L, Baldacchini F, Vattiato R, Giuliani O, Ravaioli A, Zamagni F, Bella F, Bidoli E, Caldarella A, Candela G, Carone S, Carrozzi G, Cavallo R, Ferrante M, Ferretti S, Filiberti RA, Fusco M, Gatti L, Gili A, Iacovacci S, Magoni M, Mangone L, Mazzoleni G, Michiara M, Musolino A, Piffer S, Piras D, Rizzello RV, Rosso S, Rugge M, Scala U, Stracci F, Tagliabue G, Toffolutti F, Tumino R, Biggeri A, Masini C, Ridolfi L, Villani S, Palmieri G, Stanganelli I, and Falcini F
Subjects: Male, Humans, Female, Italy epidemiology, Biopsy, Immune Checkpoint Inhibitors, Molecular Targeted Therapy, Melanoma epidemiology
Abstract: A recent research project using data from a total of 40 cancer registries has provided new epidemiologic insights into the results of efforts for melanoma control in Italy between the 1990s and the last decade. In this article, the authors present a summary and a commentary of their findings. Incidence increased significantly throughout the study period in both sexes. However, the rates showed a stabilization or a decrease in men and women aged below 35 years. The risk of disease increased for successive cohorts born until 1973 (women) and 1975 (men) while subsequently tending to decline. The trend towards decreasing tumor thickness and increasing survival has continued, but a novel favorable prognostic factor has emerged since 2013 for patients - particularly for males - with thick melanoma, most likely represented by molecular targeted therapies and immune checkpoint inhibitors. Due to this, the survival gap between males and females has been filled out. In the meanwhile, and despite the incidence increase, dermatologists have not lowered their threshold to perform skin biopsy. Skin biopsy rate has increased because of the increasingly greater volume of dermatologic office visits, but the proportion of skin biopsies out of dermatologic office visits has remained constant. In summary, an important breakthrough in melanoma control in Italy has taken place. Effective interventions have been implemented across the full scope of care, which involve many large local populations - virtually the whole national population. The strategies adopted during the last three decades represent a valuable basis for further steps ahead in melanoma control in Italy.
Published: 2023
Full Text: View/download PDF

44. Cancer and Pregnancy: Estimates in Italy from Record-Linkage Procedures between Cancer Registries and the Hospital Discharge Database.

Author: Pierannunzio D, Maraschini A, Lopez T, Donati S, Amodio R, Bianconi F, Bruni R, Castaing M, Cirilli C, Fantaci G, Guarda L, Iacovacci S, Mangone L, Mazzoleni G, Mazzucco W, Melcarne A, Merlo E, Parazzini F, Peccatori FA, Rugge M, Sampietro G, Scambia G, Scarfone G, Sferrazza A, Stracci F, Torrisi A, Vitale MF, and Francisci S
Abstract: The aim of this study is to describe the frequency and trend of pregnancy-associated cancer (PAC) in Italy, an increasingly relevant phenomenon due to postponing age at childbirth. To this purpose, a population-based retrospective longitudinal study design based on cohorts of women aged 15-49 diagnosed with cancer and concomitant pregnancy is proposed. The study uses 19 population-based Cancer Registries, covering about 22% of Italy, and linked at an individual level with Hospital Discharge Records. A total of 2,861,437 pregnancies and 3559 PAC are identified from 74,165 women of the cohort with a rate of 1.24 PAC per 1000 pregnancies. The most frequent cancer site is breast (24.3%), followed by thyroid (23.9%) and melanoma (14.3%). The most frequent outcome is delivery (53.1%), followed by voluntary termination of pregnancy and spontaneous abortion (both 12.0%). The trend of PAC increased from 2003 to 2015, especially when the outcome is delivery, thus confirming a new attitude of clinicians to manage cancer throughout pregnancy. This represents the first attempt in Italy to describe PAC from Cancer Registries data; the methodology is applicable to other areas with the same data availability. Evidence from this study is addressed to clinicians for improving clinical management of women with PAC.
Published: 2023
Full Text: View/download PDF

45. Patient presentation, skin biopsy utilization and cutaneous malignant melanoma incidence and mortality in northern Italy: Trends and correlations.

Author: Bucchi L, Mancini S, Zamagni F, Crocetti E, Dal Maso L, Ferretti S, Baldacchini F, Giuliani O, Ravaioli A, Vattiato R, Brustolin A, Candela G, Carone S, Carrozzi G, Cavallo R, Dinaro YM, Ferrante M, Iacovacci S, Mazzoleni G, Musolino A, Rizzello RV, Serraino D, Biggeri A, Stanganelli I, and Falcini F
Subjects: Male, Humans, Female, Incidence, Italy epidemiology, Melanoma, Cutaneous Malignant, Skin Neoplasms pathology, Melanoma diagnosis, Melanoma epidemiology
Abstract: Background: The global increase in incidence of cutaneous malignant melanoma (CMM) occurring in the past decades has been partly attributed to increased diagnostic scrutiny of early lesions, with a potential phenomenon of overdiagnosis. The reported positive linear relation between skin biopsy rate and incidence of early CMM is compatible with this hypothesis., Objectives: We explored the ecological association between the trends in annual dermatologic office visit rates, skin biopsy rates, incidence rates of in situ and invasive CMM by tumour thickness category, and CMM mortality rates in the Emilia-Romagna Region (northern Italy)., Methods: Four cancer registries covering a population of 2,696,000 provided CMM incidence data for the years 2003-2017. Dermatologic office visit rates and skin biopsy rates were calculated using the Regional outpatient care database. All rates were age-standardized. Trends were described with the estimated average annual per cent change (EAAPC). Correlations were tested with the Spearman correlation coefficient., Results: Incidence increased significantly. The increase was steeper for in situ CMM (EAAPC: men, 10.2; women, 6.9) followed by CMM <0.8 mm thick (9.1; 5.2), but the rates grew significantly for most subgroups of CMMs ≥0.8 mm thick. Mortality decreased significantly among women (-2.3) and non-significantly among men. For dermatologic office visit rate and skin biopsy rate the EAAPC were, respectively, 1.7 and 1.8 for men and 1.2 and 0.9 for women. Annual dermatologic office visit rate correlated with skin biopsy rate in both sexes. However, the proportion of skin biopsies out of dermatologic office visits was constant across the years (range: men, 0.182-0.216; women, 0.157-0.191)., Conclusions: In Italy, the increasing CMM incidence trend is, at least in part, genuine. Overdiagnosis-if any-is due to an increased patient presentation at dermatologic offices and not to a lower dermatologic threshold to perform biopsy., (© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)
Published: 2023
Full Text: View/download PDF

46. The relative contribution of the decreasing trend in tumour thickness to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population-based investigation.

Author: Zamagni F, Bucchi L, Mancini S, Crocetti E, Dal Maso L, Ferretti S, Biggeri A, Villani S, Baldacchini F, Giuliani O, Ravaioli A, Vattiato R, Brustolin A, Candela G, Carone S, Carrozzi G, Cavallo R, Dinaro YM, Ferrante M, Iacovacci S, Mazzoleni G, Musolino A, Rizzello RV, Serraino D, Stracci F, Tumino R, Masini C, Ridolfi L, Palmieri G, Stanganelli I, and Falcini F
Subjects: Female, Humans, Italy epidemiology, Male, Prognosis, Registries, Melanoma, Cutaneous Malignant, Melanoma pathology, Skin Neoplasms pathology
Abstract: Background: The long-term increase in survival from cutaneous malignant melanoma (CMM) is generally attributed to the decreasing trend in tumour thickness, the single most important prognostic factor., Objectives: To determine the relative contribution of decreased tumour thickness to the favourable trend in survival from CMM in Italy., Methods: Eleven local cancer registries covering a population of 8 056 608 (13.4% of the Italian population in 2010) provided records for people with primary CMM registered between 2003 and 2017. Age-standardized 5-year net survival was calculated. Multivariate analysis of 5-year net survival was undertaken by calculating the relative excess risk (RER) of death. The relative contribution of the decrease in tumour thickness to the RER of death was evaluated using a forward stepwise flexible parametric survival model including the available prognostic factors., Results: Over the study period, tumour thickness was inversely associated with 5-year net survival and multivariate RER in both sexes. The median thickness was 0.90 mm in 2003-2007, 0.85 mm in 2008-2012 and 0.75 mm in 2013-2017 among male patients, and 0.78 mm, 0.77 mm and 0.68 mm among female patients, respectively. The 5-year net survival was 86.8%, 89.2% and 93.2% in male patients, and 91.4%, 92.0% and 93.4% in female patients, respectively. In 2013-2017, male patients exhibited the same survival as female patients despite having thicker lesions. For them, the increasing survival trend was more pronounced with increasing thickness, and the inclusion of thickness in the forward stepwise model made the RER in 2013-2017 vs. 2003-2007 increase from 0.64 [95% confidence interval (CI) 0.51-0.80] to 0.70 (95% CI 0.57-0.86). This indicates that the thickness trend accounted for less than 20% of the survival increase. For female patients, the results were not significant but, with multiple imputation of missing thickness values, the RER rose from 0.74 (95% CI 0.58-0.93) to 0.82 (95% CI 0.66-1.02) in 2013-2017., Conclusions: For male patients in particular, decrease in tumour thickness accounted for a small part of the improvement in survival observed in 2013-2017. The introduction of targeted therapies and immune checkpoint inhibitors in 2013 is most likely to account for the remaining improvement., (© 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.)
Published: 2022
Full Text: View/download PDF

47. Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort.

Author: Trama A, Tittarelli A, Barigelletti G, Botta L, Gatta G, Tagliabue G, Contiero P, Guzzinati S, Andreano A, Manneschi G, Falcini F, Castaing M, Filiberti RA, Gasparotti C, Cirilli C, Mazzucco W, Mangone L, Iacovacci S, Vitale MF, Stracci F, Piffer S, Tumino R, Carone S, Sampietro G, Melcarne A, Ballotari P, Boschetti L, Pisani S, Cavalieri D'Oro L, Cuccaro F, D'Argenzio A, D'Orsi G, Fanetti AC, Ardizzone A, Candela G, Savoia F, Pascucci C, Castelli M, Storchi C, and Bernasconi A
Subjects: Adolescent, Adult, Female, Humans, Incidence, Male, Retrospective Studies, Risk Factors, Young Adult, Breast Neoplasms, Cancer Survivors, Neoplasms epidemiology, Neoplasms, Second Primary diagnosis, Neoplasms, Second Primary epidemiology
Abstract: Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scarce. This study assessed the risk of subsequent malignant neoplasms (SMNs) to identify the most common SMNs to be considered in follow-up care., Methods: Population-based cancer registries retrospectively identified first primary tumors (between 1976 and 2013) and SMNs in AYAs (15-39 years old at their cancer diagnosis). AYA cancer survivors were those alive at least 5 years after their first cancer diagnosis. The excess risk of SMNs was measured as standardized incidence ratios (SIRs) and absolute excess risk together with the cumulative incidence of SMNs., Results: The cohort included 67,692 AYA cancer survivors. The excess risk of developing any SMN (SIR, 1.6; 95% confidence interval, 1.5-1.7) was 60%. The excess risk of SMNs was significantly high for survivors of lymphomas; cancers of the breast, thyroid, female genital tract, digestive organs, gonads, and urinary tract; and melanomas. The cumulative incidence of all SMNs in AYA cancer survivors within 25 years of their first cancer diagnosis was approximately 10%. Subsequent tumors contributing to approximately 60% of all SMNs were breast cancer, colorectal cancer, corpus uteri cancer, and ovarian cancer in females and colorectal cancer, bladder cancer, prostate cancer, lung cancer, and lymphomas in males., Conclusions: These results highlight the need to personalize follow-up strategies for AYA cancer survivors., (© 2021 American Cancer Society.)
Published: 2022
Full Text: View/download PDF

48. Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012.

Author: Crocetti E, Mattioli V, Buzzoni C, Franceschi S, Serraino D, Vaccarella S, Ferretti S, Busco S, Fedeli U, Varvarà M, Falcini F, Zorzi M, Carrozzi G, Mazzucco W, Gasparotti C, Iacovacci S, Toffolutti F, Cavallo R, Stracci F, Russo AG, Caldarella A, Rosso S, Musolino A, Mangone L, Casella C, Fusco M, Tagliabue G, Piras D, Tumino R, Guarda L, Dinaro YM, Piffer S, Pinna P, Mazzoleni G, Fanetti AC, and Dal Maso L
Subjects: Cohort Studies, Female, History, 20th Century, History, 21st Century, Humans, Incidence, Italy, Male, Neoplasms, Second Primary epidemiology, Registries, Risk Factors, Thyroid Neoplasms epidemiology, Neoplasms, Second Primary pathology, Thyroid Neoplasms complications
Abstract: Background: The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC., Methods: We analyzed two population-based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population-based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer., Results: A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12-1.21) for SPC in TC patients, though no increase was shown for people with follicular (1.06) and medullary (0.95) TC. SPC with significantly increased SIRs was bone/soft tissue (2.0), breast (1.2), prostate (1.4), kidney (2.2), and hemolymphopoietic (1.4) cancers. The overall SIR for TC as a SPC was 1.49 (95% CI: 1.42-1.55), similar for all TC subtypes, and it was significantly increased for people diagnosed with head and neck (2.1), colon-rectum (1.4), lung (1.8), melanoma (2.0), bone/soft tissue (2.8), breast (1.3), corpus uteri (1.4), prostate (1.5), kidney (3.2), central nervous system (2.3), and hemolymphopoietic (1.8) cancers., Conclusions: The increased risk of TC after many other neoplasms and of few SPC after TC questions the best way to follow-up cancer patients, avoiding overdiagnosis and overtreatment for TC and, possibly, for other malignancies., (© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
Published: 2021
Full Text: View/download PDF

49. The Economic Impact of Rectal Cancer: A Population-Based Study in Italy

Author: Gigli A, Francisci S, Capodaglio G, Pierannunzio D, Mallone S, Tavilla A, Lopez T, Zorzi M, Stracci F, Busco S, Mazzucco W, Lonardi S, Bianconi F, Russo AG, Iacovacci S, Serraino D, Manneschi G, Fusco M, Cusimano R, Rugge M, and Guzzinati S
Subjects: Cross-Sectional Studies, Delivery of Health Care, Health Care Costs, Humans, Italy epidemiology, Health Expenditures, Rectal Neoplasms diagnosis, Rectal Neoplasms epidemiology, Rectal Neoplasms therapy
Abstract: Costs of cancer care are increasing worldwide, and sustainability of cancer burden is critical. In this study, the economic impact of rectal cancer on the Italian healthcare system, measured as public healthcare expenditure related to investigation and treatment of rectal cancer patients is estimated. A cross-sectional cohort of 9358 rectal cancer patients is linked, on an individual basis, to claims associated to rectal cancer diagnosis and treatments. Costs refer mainly to years 2010-2011 and are estimated by phase of care, as healthcare needs vary along the care pathway: diagnostic procedures are mainly provided in the first year, surveillance procedures are addressed to chronically ill patients, and end-of-life procedures are given in the terminal status. Clinical approaches and corresponding costs are specific by cancer type and vary by phase of care, stage at diagnosis, and age. Surgery is undertaken by the great majority of patients. Thus, hospitalization is the main cost driver. The evidence produced can be used to improve planning and allocation of healthcare resources. In particular, early diagnosis of rectal cancer is a gain in healthcare budget. Policies raising spreading of and adherence to screening plans, above all when addressed to people living in Southern Italy, should be strongly encouraged., Competing Interests: The authors declare no conflict of interest.
Published: 2021
Full Text: View/download PDF

50. Adolescent and Young Adult Cancer Survivors: Design and Characteristics of the First Nationwide Population-Based Cohort in Italy.

Author: Bernasconi A, Barigelletti G, Tittarelli A, Botta L, Gatta G, Tagliabue G, Contiero P, Guzzinati S, Andreano A, Manneschi G, Falcini F, Castaing M, Filiberti RA, Gasparotti C, Cirilli C, Mazzucco W, Mangone L, Iacovacci S, Vitale MF, Stracci F, Piffer S, Tumino R, Carone S, Sampietro G, Melcarne A, Ballotari P, Boschetti L, Pisani S, Cavalieri D'Oro L, Cuccaro F, D'Argenzio A, D'Orsi G, Fanetti AC, Ardizzone A, Candela G, Savoia F, Pascucci C, Castelli M, Storchi C, and Trama A
Subjects: Adolescent, Adult, Cohort Studies, Female, Humans, Italy, Male, Young Adult, Cancer Survivors
Abstract: Purpose: Adolescent and young adult (AYA, 15-39 years) cancer survivors (alive at least 5 years after cancer diagnosis) are less studied than younger and older cancer survivors and research on their late effects is limited. To facilitate research on long-term outcomes of AYA cancer survivors, we established, in Italy, a population-based AYA cancer survivors' cohort. This article describes the study design and main characteristics of this cohort. Methods: The cohort derives from population-based cancer registries (CRs). Each CR identified AYA cancer patients retrospectively. Treatment for first primary cancer and all health events from diagnosis to death can be traced through linkage with available health databases, such as hospital discharge records (HDRs), mortality files, and outpatient and pharmaceutical databases. Results: Thirty-four CRs participated to the cohort which overall includes 93,291 AYAs with cancer and 67,692 cancer survivors. First primary cancer distribution in AYA cancer survivors differs by sex and age groups because of the different cancer types diagnosed in AYAs. Almost 78% of AYA cancer survivors have HDRs and 14.8% also pharmaceutical and outpatient databases. Conclusion: This cohort will be used to study, for the first time in Italy, the pattern and excess risk of late effects in AYA cancer survivors. HDRs, outpatient and pharmaceutical databases will be used to define primary treatment to assess its impact on AYA cancer survivors' late effects. This cohort exploiting data sources already available at CRs, minimize the data collection effort and it will contribute to assess the feasibility of using administrative database to study cancer survivors' late effects.
Published: 2020
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

80 results on '"Iacovacci S"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources